! The Capitol Complex is open to the public with some limitations. All meetings are still available virtually online. Please visit the Capitol Information page for details.

Download Zipped Enrolled WordPerfect HB0023.ZIP
[Introduced][Amended][Status][Bill Documents][Fiscal Note][Bills Directory]

H.B. 23 Enrolled

             1     

CONTROLLED SUBSTANCE MODIFICATIONS

             2     
2011 GENERAL SESSION

             3     
STATE OF UTAH

             4     
Chief Sponsor: Gage Froerer

             5     
Senate Sponsor: Allen M. Christensen

             6      Cosponsors:
             7      Roger E. Barrus
             8      Jackie Biskupski
             9      David G. Butterfield
             10      Tim M. Cosgrove
             11      Fred C. Cox
             12      Steve Eliason
             13      Brad J. GalvezChristopher N. Herrod
Don L. Ipson
Michael T. Morley
Val L. Peterson
Dixon M. Pitcher
Paul Ray
Douglas Sagers
Stephen E. SandstromDean Sanpei
Jennifer M. Seelig
Kenneth W. Sumsion
Evan J. Vickers
Christine F. Watkins
R. Curt Webb
Ryan D. Wilcox              14     
             15      LONG TITLE
             16      General Description:
             17          This bill modifies provisions relating to the Utah Controlled Substances Act by creating
             18      a controlled class of listed synthetic cannabinoid substances found in products often
             19      referred to as "spice."
             20      Highlighted Provisions:
             21          This bill:
             22          .    expands the definition of a controlled substance to include a list of synthetic
             23      equivalent cannabinoid substances and their analogs and homologs found in
             24      products commonly referred to as "spice";
             25          .    expands the definition of a controlled substance to include substances and their
             26      analogs and homologs found in products referred to as "bath salts";
             27          .    clarifies that the tetrahydrocannabinols in Schedule I of the Utah Controlled
             28      Substances Act include those both naturally and synthetically derived;
             29          .    provides that it is an affirmative defense that the person produced, possessed, or
             30      administered any of these listed substances if the person:
             31              .    was engaged in medical research; and


             32              .    was a holder of a license to possess controlled substances for research;
             33          .    authorizes the Controlled Substances Advisory Committee to recommend
             34      placement of a substance on a controlled substance list if it finds that the substance
             35      has a potential for abuse and that an accepted standard has not been established for
             36      safe use in treatment for medical purposes;
             37          .    adds "spice" to the driver license provisions regarding driving under the influence;
             38      and
             39          .    provides that a legislative body of a political subdivision may not enact an
             40      ordinance that is less restrictive than any provision of the Utah Controlled
             41      Substances Act.
             42      Money Appropriated in this Bill:
             43          None
             44      Other Special Clauses:
             45          This bill provides an effective date.
             46      Utah Code Sections Affected:
             47      AMENDS:
             48          41-6a-517, as last amended by Laws of Utah 2009, Chapter 390
             49          58-37-2 (Superseded 07/01/11), as last amended by Laws of Utah 2010, Chapters 64
             50      and 101
             51          58-37-2 (Effective 07/01/11), as last amended by Laws of Utah 2010, Chapters 64, 101,
             52      and 276
             53          58-37-3, as last amended by Laws of Utah 1997, Chapter 64
             54          58-37-4, as last amended by Laws of Utah 2010, Chapter 106
             55          58-37-6, as last amended by Laws of Utah 2010, Chapter 287
             56          58-37-8, as last amended by Laws of Utah 2010, Chapter 64
             57          58-38a-203, as enacted by Laws of Utah 2010, Chapter 231
             58          58-38a-204, as enacted by Laws of Utah 2010, Chapter 231
             59      ENACTS:


             60          58-37-4.2, Utah Code Annotated 1953
             61     
             62      Be it enacted by the Legislature of the state of Utah:
             63          Section 1. Section 41-6a-517 is amended to read:
             64           41-6a-517. Definitions -- Driving with any measurable controlled substance in the
             65      body -- Penalties -- Arrest without warrant.
             66          (1) As used in this section:
             67          (a) "Controlled substance" [means any substance scheduled under Section 58-37-4 .]
             68      has the same meaning as in Section 58-37-2 .
             69          (b) "Practitioner" has the same meaning as [provided] in Section 58-37-2 .
             70          (c) "Prescribe" has the same meaning as [provided] in Section 58-37-2 .
             71          (d) "Prescription" has the same meaning as [provided] in Section 58-37-2 .
             72          (2) In cases not amounting to a violation of Section 41-6a-502 , a person may not
             73      operate or be in actual physical control of a motor vehicle within this state if the person has any
             74      measurable controlled substance or metabolite of a controlled substance in the person's body.
             75          (3) It is an affirmative defense to prosecution under this section that the controlled
             76      substance was:
             77          (a) involuntarily ingested by the accused;
             78          (b) prescribed by a practitioner for use by the accused; or
             79          (c) otherwise legally ingested.
             80          (4) (a) A person convicted of a violation of Subsection (2) is guilty of a class B
             81      misdemeanor.
             82          (b) A person who violates this section is subject to conviction and sentencing under
             83      both this section and any applicable offense under Section 58-37-8 .
             84          (5) A peace officer may, without a warrant, arrest a person for a violation of this
             85      section when the officer has probable cause to believe the violation has occurred, although not
             86      in the officer's presence, and if the officer has probable cause to believe that the violation was
             87      committed by the person.


             88          (6) The Driver License Division shall:
             89          (a) if the person is 21 years of age or older on the date of arrest:
             90          (i) suspend, for a period of 120 days, the driver license of a person convicted under
             91      Subsection (2) of an offense committed on or after July 1, 2009; or
             92          (ii) revoke, for a period of two years, the driver license of a person if:
             93          (A) the person has a prior conviction as defined under Subsection 41-6a-501 (2); and
             94          (B) the current violation under Subsection (2) is committed:
             95          (I) within a period of 10 years after the date of the prior violation; and
             96          (II) on or after July 1, 2009;
             97          (b) if the person is under 21 years of age on the date of arrest:
             98          (i) suspend, until the person is 21 years of age or for a period of 120 days, the driver
             99      license of a person convicted under Subsection (2) of an offense committed on or after July 1,
             100      2009; or
             101          (ii) revoke, until the person is 21 years of age or for a period of two years, the driver
             102      license of a person if:
             103          (A) the person has a prior conviction as defined under Subsection 41-6a-501 (2); and
             104          (B) the current violation under Subsection (2) is committed:
             105          (I) within a period of 10 years after the date of the prior violation; and
             106          (II) on or after July 1, 2009;
             107          (c) subtract from any suspension or revocation period the number of days for which a
             108      license was previously suspended under Section 53-3-223 or 53-3-231 , if the previous
             109      suspension was based on the same occurrence upon which the record of conviction is based;
             110      and
             111          (d) deny, suspend, or revoke a person's license for the denial and suspension periods in
             112      effect prior to July 1, 2009, for a conviction of a violation under Subsection (2) that was
             113      committed prior to July 1, 2009.
             114          (7) (a) The court shall notify the Driver License Division if a person fails to:
             115          (i) complete all court ordered screening and assessment, educational series, and


             116      substance abuse treatment; or
             117          (ii) pay all fines and fees, including fees for restitution and treatment costs.
             118          (b) Upon receiving the notification, the division shall suspend the person's driving
             119      privilege in accordance with Subsections 53-3-221 (2) and (3).
             120          (8) The court shall order supervised probation in accordance with Section 41-6a-507
             121      for a person convicted under Subsection (2).
             122          Section 2. Section 58-37-2 (Superseded 07/01/11) is amended to read:
             123           58-37-2 (Superseded 07/01/11). Definitions.
             124          (1) As used in this chapter:
             125          (a) "Administer" means the direct application of a controlled substance, whether by
             126      injection, inhalation, ingestion, or any other means, to the body of a patient or research subject
             127      by:
             128          (i) a practitioner or, in the practitioner's presence, by the practitioner's authorized agent;
             129      or
             130          (ii) the patient or research subject at the direction and in the presence of the
             131      practitioner.
             132          (b) "Agent" means an authorized person who acts on behalf of or at the direction of a
             133      manufacturer, distributor, or practitioner but does not include a motor carrier, public
             134      warehouseman, or employee of any of them.
             135          (c) "Consumption" means ingesting or having any measurable amount of a controlled
             136      substance in a person's body, but this Subsection (1)(c) does not include the metabolite of a
             137      controlled substance.
             138          (d) "Continuing criminal enterprise" means any individual, sole proprietorship,
             139      partnership, corporation, business trust, association, or other legal entity, and any union or
             140      groups of individuals associated in fact although not a legal entity, and includes illicit as well
             141      as licit entities created or maintained for the purpose of engaging in conduct which constitutes
             142      the commission of episodes of activity made unlawful by Title 58, Chapter 37, Utah Controlled
             143      Substances Act, Chapter 37a, Utah Drug Paraphernalia Act, Chapter 37b, Imitation Controlled


             144      Substances Act, Chapter 37c, Utah Controlled Substance Precursor Act, or Chapter 37d,
             145      Clandestine Drug Lab Act, which episodes are not isolated, but have the same or similar
             146      purposes, results, participants, victims, methods of commission, or otherwise are interrelated
             147      by distinguishing characteristics. Taken together, the episodes shall demonstrate continuing
             148      unlawful conduct and be related either to each other or to the enterprise.
             149          (e) "Control" means to add, remove, or change the placement of a drug, substance, or
             150      immediate precursor under Section 58-37-3 .
             151          (f) (i) "Controlled substance" means a drug or substance:
             152          (A) included in Schedules I, II, III, IV, or V of Section 58-37-4 ;
             153          (B) included in Schedules I, II, III, IV, or V of the federal Controlled Substances Act,
             154      Title II, P.L. 91-513; [or]
             155          (C) that is a controlled substance analog[.]; or
             156          (D) listed in Section 58-37-4.2 .
             157          (ii) "Controlled substance" does not include:
             158          (A) distilled spirits, wine, or malt beverages, as those terms are defined in Title 32A,
             159      Alcoholic Beverage Control Act;
             160          (B) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment, or
             161      prevention of disease in human or other animals, which contains ephedrine, pseudoephedrine,
             162      norpseudoephedrine, or phenylpropanolamine if the drug is lawfully purchased, sold,
             163      transferred, or furnished as an over-the-counter medication without prescription; or
             164          (C) dietary supplements, vitamins, minerals, herbs, or other similar substances
             165      including concentrates or extracts, which:
             166          (I) are not otherwise regulated by law; and
             167          (II) may contain naturally occurring amounts of chemical or substances listed in this
             168      chapter, or in rules adopted pursuant to Title 63G, Chapter 3, Utah Administrative Rulemaking
             169      Act.
             170          (g) (i) "Controlled substance analog" means a substance the chemical structure of
             171      which is substantially similar to the chemical structure of a controlled substance listed in


             172      Schedules I and II of Section 58-37-4 , or in Schedules I and II of the federal Controlled
             173      Substances Act, Title II, P.L. 91-513, or listed in Section 58-37-4.2 :
             174          (A) which has a stimulant, depressant, or hallucinogenic effect on the central nervous
             175      system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central
             176      nervous system of controlled substances in the schedules set forth in Subsection (1)(f), or a
             177      substance listed in Section 58-37-4.2 ; or
             178          (B) which, with respect to a particular individual, is represented or intended to have a
             179      stimulant, depressant, or hallucinogenic effect on the central nervous system substantially
             180      similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of
             181      controlled substances in the schedules or list set forth in this Subsection (1).
             182          (ii) "Controlled substance analog" does not include:
             183          (A) a controlled substance currently scheduled in Schedules I through V of Section
             184      58-37-4 or listed in Section 58-37-4.2 ;
             185          (B) a substance for which there is an approved new drug application;
             186          (C) a substance with respect to which an exemption is in effect for investigational use
             187      by a particular person under Section 505 of the Food, Drug, and Cosmetic Act, 21 U.S.C. 355,
             188      to the extent the conduct with respect to the substance is permitted by the exemption;
             189          (D) any substance to the extent not intended for human consumption before an
             190      exemption takes effect with respect to the substance;
             191          (E) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment, or
             192      prevention of disease in man or other animals, which contains ephedrine, pseudoephedrine,
             193      norpseudoephedrine, or phenylpropanolamine if the drug is lawfully purchased, sold,
             194      transferred, or furnished as an over-the-counter medication without prescription; or
             195          (F) dietary supplements, vitamins, minerals, herbs, or other similar substances
             196      including concentrates or extracts, which are not otherwise regulated by law, which may
             197      contain naturally occurring amounts of chemical or substances listed in this chapter, or in rules
             198      adopted pursuant to Title 63G, Chapter 3, Utah Administrative Rulemaking Act.
             199          (h) "Conviction" means a determination of guilt by verdict, whether jury or bench, or


             200      plea, whether guilty or no contest, for any offense proscribed by Title 58, Chapters 37, 37a,
             201      37b, 37c, or 37d, or for any offense under the laws of the United States and any other state
             202      which, if committed in this state, would be an offense under Title 58, Chapters 37, 37a, 37b,
             203      37c, or 37d.
             204          (i) "Counterfeit substance" means:
             205          (i) any controlled substance or container or labeling of any controlled substance that:
             206          (A) without authorization bears the trademark, trade name, or other identifying mark,
             207      imprint, number, device, or any likeness of them, of a manufacturer, distributor, or dispenser
             208      other than the person or persons who in fact manufactured, distributed, or dispensed the
             209      substance which falsely purports to be a controlled substance distributed by any other
             210      manufacturer, distributor, or dispenser; and
             211          (B) a reasonable person would believe to be a controlled substance distributed by an
             212      authorized manufacturer, distributor, or dispenser based on the appearance of the substance as
             213      described under Subsection (1)(i)(i)(A) or the appearance of the container of that controlled
             214      substance; or
             215          (ii) any substance other than under Subsection (1)(i)(i) that:
             216          (A) is falsely represented to be any legally or illegally manufactured controlled
             217      substance; and
             218          (B) a reasonable person would believe to be a legal or illegal controlled substance.
             219          (j) "Deliver" or "delivery" means the actual, constructive, or attempted transfer of a
             220      controlled substance or a listed chemical, whether or not an agency relationship exists.
             221          (k) "Department" means the Department of Commerce.
             222          (l) "Depressant or stimulant substance" means:
             223          (i) a drug which contains any quantity of barbituric acid or any of the salts of barbituric
             224      acid;
             225          (ii) a drug which contains any quantity of:
             226          (A) amphetamine or any of its optical isomers;
             227          (B) any salt of amphetamine or any salt of an optical isomer of amphetamine; or


             228          (C) any substance which the Secretary of Health and Human Services or the Attorney
             229      General of the United States after investigation has found and by regulation designated
             230      habit-forming because of its stimulant effect on the central nervous system;
             231          (iii) lysergic acid diethylamide; or
             232          (iv) any drug which contains any quantity of a substance which the Secretary of Health
             233      and Human Services or the Attorney General of the United States after investigation has found
             234      to have, and by regulation designated as having, a potential for abuse because of its depressant
             235      or stimulant effect on the central nervous system or its hallucinogenic effect.
             236          (m) "Dispense" means the delivery of a controlled substance by a pharmacist to an
             237      ultimate user pursuant to the lawful order or prescription of a practitioner, and includes
             238      distributing to, leaving with, giving away, or disposing of that substance as well as the
             239      packaging, labeling, or compounding necessary to prepare the substance for delivery.
             240          (n) "Dispenser" means a pharmacist who dispenses a controlled substance.
             241          (o) "Distribute" means to deliver other than by administering or dispensing a controlled
             242      substance or a listed chemical.
             243          (p) "Distributor" means a person who distributes controlled substances.
             244          (q) "Division" means the Division of Occupational and Professional Licensing created
             245      in Section 58-1-103 .
             246          (r) (i) "Drug" means:
             247          (A) a substance recognized in the official United States Pharmacopoeia, Official
             248      Homeopathic Pharmacopoeia of the United States, or Official National Formulary, or any
             249      supplement to any of them, intended for use in the diagnosis, cure, mitigation, treatment, or
             250      prevention of disease in humans or animals;
             251          (B) a substance that is required by any applicable federal or state law or rule to be
             252      dispensed by prescription only or is restricted to administration by practitioners only;
             253          (C) a substance other than food intended to affect the structure or any function of the
             254      body of humans or other animals; and
             255          (D) substances intended for use as a component of any substance specified in


             256      Subsections (1)(r)(i)(A), (B), and (C)[, and (D)].
             257          (ii) "Drug" does not include dietary supplements.
             258          (s) "Drug dependent person" means any individual who unlawfully and habitually uses
             259      any controlled substance to endanger the public morals, health, safety, or welfare, or who is so
             260      dependent upon the use of controlled substances as to have lost the power of self-control with
             261      reference to the individual's dependency.
             262          (t) "Food" means:
             263          (i) any nutrient or substance of plant, mineral, or animal origin other than a drug as
             264      specified in this chapter, and normally ingested by human beings; and
             265          (ii) foods for special dietary uses as exist by reason of a physical, physiological,
             266      pathological, or other condition including but not limited to the conditions of disease,
             267      convalescence, pregnancy, lactation, allergy, hypersensitivity to food, underweight, and
             268      overweight; uses for supplying a particular dietary need which exist by reason of age including
             269      but not limited to the ages of infancy and childbirth, and also uses for supplementing and for
             270      fortifying the ordinary or unusual diet with any vitamin, mineral, or other dietary property for
             271      use of a food. Any particular use of a food is a special dietary use regardless of the nutritional
             272      purposes.
             273          (u) "Immediate precursor" means a substance which the Attorney General of the United
             274      States has found to be, and by regulation designated as being, the principal compound used or
             275      produced primarily for use in the manufacture of a controlled substance, or which is an
             276      immediate chemical intermediary used or likely to be used in the manufacture of a controlled
             277      substance, the control of which is necessary to prevent, curtail, or limit the manufacture of the
             278      controlled substance.
             279          (v) "Indian" means a member of an Indian tribe.
             280          (w) "Indian religion" means any religion:
             281          (i) the origin and interpretation of which is from within a traditional Indian culture or
             282      community; and
             283          (ii) which is practiced by Indians.


             284          (x) "Indian tribe" means any tribe, band, nation, pueblo, or other organized group or
             285      community of Indians, including any Alaska Native village, which is legally recognized as
             286      eligible for and is consistent with the special programs, services, and entitlements provided by
             287      the United States to Indians because of their status as Indians.
             288          (y) "Manufacture" means the production, preparation, propagation, compounding, or
             289      processing of a controlled substance, either directly or indirectly by extraction from substances
             290      of natural origin, or independently by means of chemical synthesis or by a combination of
             291      extraction and chemical synthesis.
             292          (z) "Manufacturer" includes any person who packages, repackages, or labels any
             293      container of any controlled substance, except pharmacists who dispense or compound
             294      prescription orders for delivery to the ultimate consumer.
             295          (aa) "Marijuana" means all species of the genus cannabis and all parts of the genus,
             296      whether growing or not; the seeds of it; the resin extracted from any part of the plant; and every
             297      compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds, or
             298      resin. The term does not include the mature stalks of the plant, fiber produced from the stalks,
             299      oil or cake made from the seeds of the plant, any other compound, manufacture, salt,
             300      derivative, mixture, or preparation of the mature stalks, except the resin extracted from them,
             301      fiber, oil or cake, or the sterilized seed of the plant which is incapable of germination. Any
             302      synthetic equivalents of the substances contained in the plant cannabis sativa or any other
             303      species of the genus cannabis which are chemically indistinguishable and pharmacologically
             304      active are also included.
             305          (bb) "Money" means officially issued coin and currency of the United States or any
             306      foreign country.
             307          (cc) "Narcotic drug" means any of the following, whether produced directly or
             308      indirectly by extraction from substances of vegetable origin, or independently by means of
             309      chemical synthesis, or by a combination of extraction and chemical synthesis:
             310          (i) opium, coca leaves, and opiates;
             311          (ii) a compound, manufacture, salt, derivative, or preparation of opium, coca leaves, or


             312      opiates;
             313          (iii) opium poppy and poppy straw; or
             314          (iv) a substance, and any compound, manufacture, salt, derivative, or preparation of the
             315      substance, which is chemically identical with any of the substances referred to in Subsection
             316      (1)(cc)(i), (ii), or (iii), except narcotic drug does not include decocainized coca leaves or
             317      extracts of coca leaves which do not contain cocaine or ecgonine.
             318          (dd) "Negotiable instrument" means documents, containing an unconditional promise
             319      to pay a sum of money, which are legally transferable to another party by endorsement or
             320      delivery.
             321          (ee) "Opiate" means any drug or other substance having an addiction-forming or
             322      addiction-sustaining liability similar to morphine or being capable of conversion into a drug
             323      having addiction-forming or addiction-sustaining liability.
             324          (ff) "Opium poppy" means the plant of the species papaver somniferum L., except the
             325      seeds of the plant.
             326          (gg) "Person" means any corporation, association, partnership, trust, other institution or
             327      entity or one or more individuals.
             328          (hh) "Poppy straw" means all parts, except the seeds, of the opium poppy, after
             329      mowing.
             330          (ii) "Possession" or "use" means the joint or individual ownership, control, occupancy,
             331      holding, retaining, belonging, maintaining, or the application, inhalation, swallowing, injection,
             332      or consumption, as distinguished from distribution, of controlled substances and includes
             333      individual, joint, or group possession or use of controlled substances. For a person to be a
             334      possessor or user of a controlled substance, it is not required that the person be shown to have
             335      individually possessed, used, or controlled the substance, but it is sufficient if it is shown that
             336      the person jointly participated with one or more persons in the use, possession, or control of
             337      any substances with knowledge that the activity was occurring, or the controlled substance is
             338      found in a place or under circumstances indicating that the person had the ability and the intent
             339      to exercise dominion and control over it.


             340          (jj) "Practitioner" means a physician, dentist, naturopathic physician, veterinarian,
             341      pharmacist, scientific investigator, pharmacy, hospital, or other person licensed, registered, or
             342      otherwise permitted to distribute, dispense, conduct research with respect to, administer, or use
             343      in teaching or chemical analysis a controlled substance in the course of professional practice or
             344      research in this state.
             345          (kk) "Prescribe" means to issue a prescription:
             346          (i) orally or in writing; or
             347          (ii) by telephone, facsimile transmission, computer, or other electronic means of
             348      communication as defined by division rule.
             349          (ll) "Prescription" means an order issued:
             350          (i) by a licensed practitioner, in the course of that practitioner's professional practice or
             351      by collaborative pharmacy practice agreement; and
             352          (ii) for a controlled substance or other prescription drug or device for use by a patient
             353      or an animal.
             354          (mm) "Production" means the manufacture, planting, cultivation, growing, or
             355      harvesting of a controlled substance.
             356          (nn) "Securities" means any stocks, bonds, notes, or other evidences of debt or of
             357      property.
             358          (oo) "State" means the state of Utah.
             359          (pp) "Ultimate user" means any person who lawfully possesses a controlled substance
             360      for the person's own use, for the use of a member of the person's household, or for
             361      administration to an animal owned by the person or a member of the person's household.
             362          (2) If a term used in this chapter is not defined, the definition and terms of Title 76,
             363      Utah Criminal Code, shall apply.
             364          Section 3. Section 58-37-2 (Effective 07/01/11) is amended to read:
             365           58-37-2 (Effective 07/01/11). Definitions.
             366          (1) As used in this chapter:
             367          (a) "Administer" means the direct application of a controlled substance, whether by


             368      injection, inhalation, ingestion, or any other means, to the body of a patient or research subject
             369      by:
             370          (i) a practitioner or, in the practitioner's presence, by the practitioner's authorized agent;
             371      or
             372          (ii) the patient or research subject at the direction and in the presence of the
             373      practitioner.
             374          (b) "Agent" means an authorized person who acts on behalf of or at the direction of a
             375      manufacturer, distributor, or practitioner but does not include a motor carrier, public
             376      warehouseman, or employee of any of them.
             377          (c) "Consumption" means ingesting or having any measurable amount of a controlled
             378      substance in a person's body, but this Subsection (1)(c) does not include the metabolite of a
             379      controlled substance.
             380          (d) "Continuing criminal enterprise" means any individual, sole proprietorship,
             381      partnership, corporation, business trust, association, or other legal entity, and any union or
             382      groups of individuals associated in fact although not a legal entity, and includes illicit as well
             383      as licit entities created or maintained for the purpose of engaging in conduct which constitutes
             384      the commission of episodes of activity made unlawful by Title 58, Chapter 37, Utah Controlled
             385      Substances Act, Chapter 37a, Utah Drug Paraphernalia Act, Chapter 37b, Imitation Controlled
             386      Substances Act, Chapter 37c, Utah Controlled Substance Precursor Act, or Chapter 37d,
             387      Clandestine Drug Lab Act, which episodes are not isolated, but have the same or similar
             388      purposes, results, participants, victims, methods of commission, or otherwise are interrelated
             389      by distinguishing characteristics. Taken together, the episodes shall demonstrate continuing
             390      unlawful conduct and be related either to each other or to the enterprise.
             391          (e) "Control" means to add, remove, or change the placement of a drug, substance, or
             392      immediate precursor under Section 58-37-3 .
             393          (f) (i) "Controlled substance" means a drug or substance:
             394          (A) included in Schedules I, II, III, IV, or V of Section 58-37-4 ;
             395          (B) included in Schedules I, II, III, IV, or V of the federal Controlled Substances Act,


             396      Title II, P.L. 91-513; [or]
             397          (C) that is a controlled substance analog[.]; or
             398          (D) listed in Section 58-37-4.2 .
             399          (ii) "Controlled substance" does not include:
             400          (A) distilled spirits, wine, or malt beverages, as those terms are defined in Title 32B,
             401      Alcoholic Beverage Control Act;
             402          (B) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment, or
             403      prevention of disease in human or other animals, which contains ephedrine, pseudoephedrine,
             404      norpseudoephedrine, or phenylpropanolamine if the drug is lawfully purchased, sold,
             405      transferred, or furnished as an over-the-counter medication without prescription; or
             406          (C) dietary supplements, vitamins, minerals, herbs, or other similar substances
             407      including concentrates or extracts, which:
             408          (I) are not otherwise regulated by law; and
             409          (II) may contain naturally occurring amounts of chemical or substances listed in this
             410      chapter, or in rules adopted pursuant to Title 63G, Chapter 3, Utah Administrative Rulemaking
             411      Act.
             412          (g) (i) "Controlled substance analog" means a substance the chemical structure of
             413      which is substantially similar to the chemical structure of a controlled substance listed in
             414      Schedules I and II of Section 58-37-4 , a substance listed in Section 58-37-4.2 , or in Schedules
             415      I and II of the federal Controlled Substances Act, Title II, P.L. 91-513:
             416          (A) which has a stimulant, depressant, or hallucinogenic effect on the central nervous
             417      system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central
             418      nervous system of controlled substances in the schedules set forth in Subsection (1)(f), a
             419      substance listed in Section 58-37-4.2 ; or
             420          (B) which, with respect to a particular individual, is represented or intended to have a
             421      stimulant, depressant, or hallucinogenic effect on the central nervous system substantially
             422      similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of
             423      controlled substances in the schedules or list set forth in this Subsection (1).


             424          (ii) "Controlled substance analog" does not include:
             425          (A) a controlled substance currently scheduled in Schedules I through V of Section
             426      58-37-4 ;
             427          (B) a substance for which there is an approved new drug application;
             428          (C) a substance with respect to which an exemption is in effect for investigational use
             429      by a particular person under Section 505 of the Food, Drug, and Cosmetic Act, 21 U.S.C. 355,
             430      to the extent the conduct with respect to the substance is permitted by the exemption;
             431          (D) any substance to the extent not intended for human consumption before an
             432      exemption takes effect with respect to the substance;
             433          (E) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment, or
             434      prevention of disease in man or other animals, which contains ephedrine, pseudoephedrine,
             435      norpseudoephedrine, or phenylpropanolamine if the drug is lawfully purchased, sold,
             436      transferred, or furnished as an over-the-counter medication without prescription; or
             437          (F) dietary supplements, vitamins, minerals, herbs, or other similar substances
             438      including concentrates or extracts, which are not otherwise regulated by law, which may
             439      contain naturally occurring amounts of chemical or substances listed in this chapter, or in rules
             440      adopted pursuant to Title 63G, Chapter 3, Utah Administrative Rulemaking Act.
             441          (h) "Conviction" means a determination of guilt by verdict, whether jury or bench, or
             442      plea, whether guilty or no contest, for any offense proscribed by Title 58, Chapters 37, 37a,
             443      37b, 37c, or 37d, or for any offense under the laws of the United States and any other state
             444      which, if committed in this state, would be an offense under Title 58, Chapters 37, 37a, 37b,
             445      37c, or 37d.
             446          (i) "Counterfeit substance" means:
             447          (i) any controlled substance or container or labeling of any controlled substance that:
             448          (A) without authorization bears the trademark, trade name, or other identifying mark,
             449      imprint, number, device, or any likeness of them, of a manufacturer, distributor, or dispenser
             450      other than the person or persons who in fact manufactured, distributed, or dispensed the
             451      substance which falsely purports to be a controlled substance distributed by any other


             452      manufacturer, distributor, or dispenser; and
             453          (B) a reasonable person would believe to be a controlled substance distributed by an
             454      authorized manufacturer, distributor, or dispenser based on the appearance of the substance as
             455      described under Subsection (1)(i)(i)(A) or the appearance of the container of that controlled
             456      substance; or
             457          (ii) any substance other than under Subsection (1)(i)(i) that:
             458          (A) is falsely represented to be any legally or illegally manufactured controlled
             459      substance; and
             460          (B) a reasonable person would believe to be a legal or illegal controlled substance.
             461          (j) "Deliver" or "delivery" means the actual, constructive, or attempted transfer of a
             462      controlled substance or a listed chemical, whether or not an agency relationship exists.
             463          (k) "Department" means the Department of Commerce.
             464          (l) "Depressant or stimulant substance" means:
             465          (i) a drug which contains any quantity of barbituric acid or any of the salts of barbituric
             466      acid;
             467          (ii) a drug which contains any quantity of:
             468          (A) amphetamine or any of its optical isomers;
             469          (B) any salt of amphetamine or any salt of an optical isomer of amphetamine; or
             470          (C) any substance which the Secretary of Health and Human Services or the Attorney
             471      General of the United States after investigation has found and by regulation designated
             472      habit-forming because of its stimulant effect on the central nervous system;
             473          (iii) lysergic acid diethylamide; or
             474          (iv) any drug which contains any quantity of a substance which the Secretary of Health
             475      and Human Services or the Attorney General of the United States after investigation has found
             476      to have, and by regulation designated as having, a potential for abuse because of its depressant
             477      or stimulant effect on the central nervous system or its hallucinogenic effect.
             478          (m) "Dispense" means the delivery of a controlled substance by a pharmacist to an
             479      ultimate user pursuant to the lawful order or prescription of a practitioner, and includes


             480      distributing to, leaving with, giving away, or disposing of that substance as well as the
             481      packaging, labeling, or compounding necessary to prepare the substance for delivery.
             482          (n) "Dispenser" means a pharmacist who dispenses a controlled substance.
             483          (o) "Distribute" means to deliver other than by administering or dispensing a controlled
             484      substance or a listed chemical.
             485          (p) "Distributor" means a person who distributes controlled substances.
             486          (q) "Division" means the Division of Occupational and Professional Licensing created
             487      in Section 58-1-103 .
             488          (r) (i) "Drug" means:
             489          (A) a substance recognized in the official United States Pharmacopoeia, Official
             490      Homeopathic Pharmacopoeia of the United States, or Official National Formulary, or any
             491      supplement to any of them, intended for use in the diagnosis, cure, mitigation, treatment, or
             492      prevention of disease in humans or animals;
             493          (B) a substance that is required by any applicable federal or state law or rule to be
             494      dispensed by prescription only or is restricted to administration by practitioners only;
             495          (C) a substance other than food intended to affect the structure or any function of the
             496      body of humans or other animals; and
             497          (D) substances intended for use as a component of any substance specified in
             498      Subsections (1)(r)(i)(A), (B), and (C)[, and (D)].
             499          (ii) "Drug" does not include dietary supplements.
             500          (s) "Drug dependent person" means any individual who unlawfully and habitually uses
             501      any controlled substance to endanger the public morals, health, safety, or welfare, or who is so
             502      dependent upon the use of controlled substances as to have lost the power of self-control with
             503      reference to the individual's dependency.
             504          (t) "Food" means:
             505          (i) any nutrient or substance of plant, mineral, or animal origin other than a drug as
             506      specified in this chapter, and normally ingested by human beings; and
             507          (ii) foods for special dietary uses as exist by reason of a physical, physiological,


             508      pathological, or other condition including but not limited to the conditions of disease,
             509      convalescence, pregnancy, lactation, allergy, hypersensitivity to food, underweight, and
             510      overweight; uses for supplying a particular dietary need which exist by reason of age including
             511      but not limited to the ages of infancy and childbirth, and also uses for supplementing and for
             512      fortifying the ordinary or unusual diet with any vitamin, mineral, or other dietary property for
             513      use of a food. Any particular use of a food is a special dietary use regardless of the nutritional
             514      purposes.
             515          (u) "Immediate precursor" means a substance which the Attorney General of the United
             516      States has found to be, and by regulation designated as being, the principal compound used or
             517      produced primarily for use in the manufacture of a controlled substance, or which is an
             518      immediate chemical intermediary used or likely to be used in the manufacture of a controlled
             519      substance, the control of which is necessary to prevent, curtail, or limit the manufacture of the
             520      controlled substance.
             521          (v) "Indian" means a member of an Indian tribe.
             522          (w) "Indian religion" means any religion:
             523          (i) the origin and interpretation of which is from within a traditional Indian culture or
             524      community; and
             525          (ii) which is practiced by Indians.
             526          (x) "Indian tribe" means any tribe, band, nation, pueblo, or other organized group or
             527      community of Indians, including any Alaska Native village, which is legally recognized as
             528      eligible for and is consistent with the special programs, services, and entitlements provided by
             529      the United States to Indians because of their status as Indians.
             530          (y) "Manufacture" means the production, preparation, propagation, compounding, or
             531      processing of a controlled substance, either directly or indirectly by extraction from substances
             532      of natural origin, or independently by means of chemical synthesis or by a combination of
             533      extraction and chemical synthesis.
             534          (z) "Manufacturer" includes any person who packages, repackages, or labels any
             535      container of any controlled substance, except pharmacists who dispense or compound


             536      prescription orders for delivery to the ultimate consumer.
             537          (aa) "Marijuana" means all species of the genus cannabis and all parts of the genus,
             538      whether growing or not; the seeds of it; the resin extracted from any part of the plant; and every
             539      compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds, or
             540      resin. The term does not include the mature stalks of the plant, fiber produced from the stalks,
             541      oil or cake made from the seeds of the plant, any other compound, manufacture, salt,
             542      derivative, mixture, or preparation of the mature stalks, except the resin extracted from them,
             543      fiber, oil or cake, or the sterilized seed of the plant which is incapable of germination. Any
             544      synthetic equivalents of the substances contained in the plant cannabis sativa or any other
             545      species of the genus cannabis which are chemically indistinguishable and pharmacologically
             546      active are also included.
             547          (bb) "Money" means officially issued coin and currency of the United States or any
             548      foreign country.
             549          (cc) "Narcotic drug" means any of the following, whether produced directly or
             550      indirectly by extraction from substances of vegetable origin, or independently by means of
             551      chemical synthesis, or by a combination of extraction and chemical synthesis:
             552          (i) opium, coca leaves, and opiates;
             553          (ii) a compound, manufacture, salt, derivative, or preparation of opium, coca leaves, or
             554      opiates;
             555          (iii) opium poppy and poppy straw; or
             556          (iv) a substance, and any compound, manufacture, salt, derivative, or preparation of the
             557      substance, which is chemically identical with any of the substances referred to in Subsection
             558      (1)(cc)(i), (ii), or (iii), except narcotic drug does not include decocainized coca leaves or
             559      extracts of coca leaves which do not contain cocaine or ecgonine.
             560          (dd) "Negotiable instrument" means documents, containing an unconditional promise
             561      to pay a sum of money, which are legally transferable to another party by endorsement or
             562      delivery.
             563          (ee) "Opiate" means any drug or other substance having an addiction-forming or


             564      addiction-sustaining liability similar to morphine or being capable of conversion into a drug
             565      having addiction-forming or addiction-sustaining liability.
             566          (ff) "Opium poppy" means the plant of the species papaver somniferum L., except the
             567      seeds of the plant.
             568          (gg) "Person" means any corporation, association, partnership, trust, other institution or
             569      entity or one or more individuals.
             570          (hh) "Poppy straw" means all parts, except the seeds, of the opium poppy, after
             571      mowing.
             572          (ii) "Possession" or "use" means the joint or individual ownership, control, occupancy,
             573      holding, retaining, belonging, maintaining, or the application, inhalation, swallowing, injection,
             574      or consumption, as distinguished from distribution, of controlled substances and includes
             575      individual, joint, or group possession or use of controlled substances. For a person to be a
             576      possessor or user of a controlled substance, it is not required that the person be shown to have
             577      individually possessed, used, or controlled the substance, but it is sufficient if it is shown that
             578      the person jointly participated with one or more persons in the use, possession, or control of
             579      any substances with knowledge that the activity was occurring, or the controlled substance is
             580      found in a place or under circumstances indicating that the person had the ability and the intent
             581      to exercise dominion and control over it.
             582          (jj) "Practitioner" means a physician, dentist, naturopathic physician, veterinarian,
             583      pharmacist, scientific investigator, pharmacy, hospital, or other person licensed, registered, or
             584      otherwise permitted to distribute, dispense, conduct research with respect to, administer, or use
             585      in teaching or chemical analysis a controlled substance in the course of professional practice or
             586      research in this state.
             587          (kk) "Prescribe" means to issue a prescription:
             588          (i) orally or in writing; or
             589          (ii) by telephone, facsimile transmission, computer, or other electronic means of
             590      communication as defined by division rule.
             591          (ll) "Prescription" means an order issued:


             592          (i) by a licensed practitioner, in the course of that practitioner's professional practice or
             593      by collaborative pharmacy practice agreement; and
             594          (ii) for a controlled substance or other prescription drug or device for use by a patient
             595      or an animal.
             596          (mm) "Production" means the manufacture, planting, cultivation, growing, or
             597      harvesting of a controlled substance.
             598          (nn) "Securities" means any stocks, bonds, notes, or other evidences of debt or of
             599      property.
             600          (oo) "State" means the state of Utah.
             601          (pp) "Ultimate user" means any person who lawfully possesses a controlled substance
             602      for the person's own use, for the use of a member of the person's household, or for
             603      administration to an animal owned by the person or a member of the person's household.
             604          (2) If a term used in this chapter is not defined, the definition and terms of Title 76,
             605      Utah Criminal Code, shall apply.
             606          Section 4. Section 58-37-3 is amended to read:
             607           58-37-3. Controlled substances.
             608          (1) All substances listed in Section 58-37-4 or 58-37-4.2 are [considered] controlled.
             609          (2) All substances listed in the federal Controlled Substances Act, Title II, P.L. 91-513,
             610      are [considered] controlled.
             611          Section 5. Section 58-37-4 is amended to read:
             612           58-37-4. Schedules of controlled substances -- Schedules I through V -- Findings
             613      required -- Specific substances included in schedules.
             614          (1) There are established five schedules of controlled substances known as Schedules I,
             615      II, III, IV, and V which [shall] consist of substances listed in this section.
             616          (2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by
             617      the official name, common or usual name, chemical name, or brand name designated:
             618          (a) Schedule I:
             619          (i) Unless specifically excepted or unless listed in another schedule, any of the


             620      following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
             621      ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific
             622      chemical designation:
             623          (A) Acetyl-alpha-methylfentanyl
             624      (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
             625          (B) Acetylmethadol;
             626          (C) Allylprodine;
             627          (D) Alphacetylmethadol, except levo-alphacetylmethadol also known as
             628      levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
             629          (E) Alphameprodine;
             630          (F) Alphamethadol;
             631          (G) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]
             632      propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
             633          (H) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
             634      piperidinyl]-N-phenylpropanamide);
             635          (I) Benzethidine;
             636          (J) Betacetylmethadol;
             637          (K) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
             638      piperidinyl]-N-phenylpropanamide);
             639          (L) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-
             640      phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
             641          (M) Betameprodine;
             642          (N) Betamethadol;
             643          (O) Betaprodine;
             644          (P) Clonitazene;
             645          (Q) Dextromoramide;
             646          (R) Diampromide;
             647          (S) Diethylthiambutene;


             648          (T) Difenoxin;
             649          (U) Dimenoxadol;
             650          (V) Dimepheptanol;
             651          (W) Dimethylthiambutene;
             652          (X) Dioxaphetyl butyrate;
             653          (Y) Dipipanone;
             654          (Z) Ethylmethylthiambutene;
             655          (AA) Etonitazene;
             656          (BB) Etoxeridine;
             657          (CC) Furethidine;
             658          (DD) Hydroxypethidine;
             659          (EE) Ketobemidone;
             660          (FF) Levomoramide;
             661          (GG) Levophenacylmorphan;
             662          (HH) Morpheridine;
             663          (II) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
             664          (JJ) Noracymethadol;
             665          (KK) Norlevorphanol;
             666          (LL) Normethadone;
             667          (MM) Norpipanone;
             668          (NN) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl]
             669      propanamide;
             670          (OO) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
             671          (PP) Phenadoxone;
             672          (QQ) Phenampromide;
             673          (RR) Phenomorphan;
             674          (SS) Phenoperidine;
             675          (TT) Piritramide;


             676          (UU) Proheptazine;
             677          (VV) Properidine;
             678          (WW) Propiram;
             679          (XX) Racemoramide;
             680          (YY) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
             681          (ZZ) Tilidine;
             682          (AAA) Trimeperidine;
             683          (BBB) 3-methylfentanyl, including the optical and geometric isomers
             684      (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide); and
             685          (CCC) 3-methylthiofentanyl
             686      (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide).
             687          (ii) Unless specifically excepted or unless listed in another schedule, any of the
             688      following opium derivatives, their salts, isomers, and salts of isomers when the existence of the
             689      salts, isomers, and salts of isomers is possible within the specific chemical designation:
             690          (A) Acetorphine;
             691          (B) Acetyldihydrocodeine;
             692          (C) Benzylmorphine;
             693          (D) Codeine methylbromide;
             694          (E) Codeine-N-Oxide;
             695          (F) Cyprenorphine;
             696          (G) Desomorphine;
             697          (H) Dihydromorphine;
             698          (I) Drotebanol;
             699          (J) Etorphine (except hydrochloride salt);
             700          (K) Heroin;
             701          (L) Hydromorphinol;
             702          (M) Methyldesorphine;
             703          (N) Methylhydromorphine;


             704          (O) Morphine methylbromide;
             705          (P) Morphine methylsulfonate;
             706          (Q) Morphine-N-Oxide;
             707          (R) Myrophine;
             708          (S) Nicocodeine;
             709          (T) Nicomorphine;
             710          (U) Normorphine;
             711          (V) Pholcodine; and
             712          (W) Thebacon.
             713          (iii) Unless specifically excepted or unless listed in another schedule, any material,
             714      compound, mixture, or preparation which contains any quantity of the following hallucinogenic
             715      substances, or which contains any of their salts, isomers, and salts of isomers when the
             716      existence of the salts, isomers, and salts of isomers is possible within the specific chemical
             717      designation; as used in this Subsection (2)(iii) only, "isomer" includes the optical, position, and
             718      geometric isomers:
             719          (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase;
             720      .-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; .-ET; and AET;
             721          (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:
             722      4-bromo-2,5-dimethoxy-.-methylphenethylamine; 4-bromo-2,5-DMA;
             723          (C) 4-bromo-2,5-dimethoxypenethylamine, some trade or other names:
             724      2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;
             725          (D) 2,5-dimethoxyamphetamine, some trade or other names:
             726      2,5-dimethoxy-.-methylphenethylamine; 2,5-DMA;
             727          (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
             728          (F) 4-methoxyamphetamine, some trade or other names:
             729      4-methoxy-.-methylphenethylamine; paramethoxyamphetamine, PMA;
             730          (G) 5-methoxy-3,4-methylenedioxyamphetamine;
             731          (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:


             732      4-methyl-2,5-dimethoxy-.-methylphenethylamine; "DOM"; and "STP";
             733          (I) 3,4-methylenedioxy amphetamine;
             734          (J) 3,4-methylenedioxymethamphetamine (MDMA);
             735          (K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-
             736      alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;
             737          (L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as
             738      N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
             739          (M) 3,4,5-trimethoxy amphetamine;
             740          (N) Bufotenine, some trade and other names:
             741      3-(.-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,
             742      N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
             743          (O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
             744          (P) Dimethyltryptamine, some trade or other names: DMT;
             745          (Q) Ibogaine, some trade and other names:
             746      7-Ethyl-6,6.,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino
             747      [5,4-b] indole; Tabernanthe iboga;
             748          (R) Lysergic acid diethylamide;
             749          (S) Marijuana;
             750          (T) Mescaline;
             751          (U) Parahexyl, some trade or other names:
             752      3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl;
             753          (V) Peyote, meaning all parts of the plant presently classified botanically as
             754      Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from
             755      any part of such plant, and every compound, manufacture, salts, derivative, mixture, or
             756      preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12));
             757          (W) N-ethyl-3-piperidyl benzilate;
             758          (X) N-methyl-3-piperidyl benzilate;
             759          (Y) Psilocybin;


             760          (Z) Psilocyn;
             761          (AA) Tetrahydrocannabinols, naturally contained in a plant of the genus Cannabis
             762      (cannabis plant), as well as synthetic equivalents of the substances contained in the cannabis
             763      plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives,
             764      and their isomers with similar chemical structure and pharmacological activity to those
             765      substances contained in the plant, such as the following: .1 cis or trans tetrahydrocannabinol,
             766      and their optical isomers .6 cis or trans tetrahydrocannabinol, and their optical isomers .3,4
             767      cis or trans tetrahydrocannabinol, and its optical isomers, and since nomenclature of these
             768      substances is not internationally standardized, compounds of these structures, regardless of
             769      numerical designation of atomic positions covered;
             770          (BB) Ethylamine analog of phencyclidine, some trade or other names:
             771      N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,
             772      N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;
             773          (CC) Pyrrolidine analog of phencyclidine, some trade or other names:
             774      1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;
             775          (DD) Thiophene analog of phencyclidine, some trade or other names:
             776      1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and
             777          (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.
             778          (iv) Unless specifically excepted or unless listed in another schedule, any material
             779      compound, mixture, or preparation which contains any quantity of the following substances
             780      having a depressant effect on the central nervous system, including its salts, isomers, and salts
             781      of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
             782      specific chemical designation:
             783          (A) Mecloqualone; and
             784          (B) Methaqualone.
             785          (v) Any material, compound, mixture, or preparation containing any quantity of the
             786      following substances having a stimulant effect on the central nervous system, including their
             787      salts, isomers, and salts of isomers:


             788          (A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or
             789      4,5-dihydro-5-phenyl-2-oxazolamine;
             790          (B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,
             791      alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;
             792          (C) Fenethylline;
             793          (D) Methcathinone, some other names: 2-(methylamino)-propiophenone;
             794      alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one;
             795      alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone;
             796      methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of
             797      optical isomers;
             798          (E) (.)cis-4-methylaminorex ((.)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
             799          (F) N-ethylamphetamine; and
             800          (G) N,N-dimethylamphetamine, also known as
             801      N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
             802          (vi) Any material, compound, mixture, or preparation which contains any quantity of
             803      the following substances, including their optical isomers, salts, and salts of isomers, subject to
             804      temporary emergency scheduling:
             805          (A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
             806          (B) N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
             807          (vii) Unless specifically excepted or unless listed in another schedule, any material,
             808      compound, mixture, or preparation which contains any quantity of gamma hydroxy butyrate
             809      (gamma hydrobutyric acid), including its salts, isomers, and salts of isomers.
             810          (b) Schedule II:
             811          (i) Unless specifically excepted or unless listed in another schedule, any of the
             812      following substances whether produced directly or indirectly by extraction from substances of
             813      vegetable origin, or independently by means of chemical synthesis, or by a combination of
             814      extraction and chemical synthesis:
             815          (A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or


             816      opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone,
             817      and their respective salts, but including:
             818          (I) Raw opium;
             819          (II) Opium extracts;
             820          (III) Opium fluid;
             821          (IV) Powdered opium;
             822          (V) Granulated opium;
             823          (VI) Tincture of opium;
             824          (VII) Codeine;
             825          (VIII) Ethylmorphine;
             826          (IX) Etorphine hydrochloride;
             827          (X) Hydrocodone;
             828          (XI) Hydromorphone;
             829          (XII) Metopon;
             830          (XIII) Morphine;
             831          (XIV) Oxycodone;
             832          (XV) Oxymorphone; and
             833          (XVI) Thebaine;
             834          (B) Any salt, compound, derivative, or preparation which is chemically equivalent or
             835      identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these
             836      substances may not include the isoquinoline alkaloids of opium;
             837          (C) Opium poppy and poppy straw;
             838          (D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
             839      any salt, compound, derivative, or preparation which is chemically equivalent or identical with
             840      any of these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives,
             841      and salts of isomers and derivatives, whether derived from the coca plant or synthetically
             842      produced, except the substances may not include decocainized coca leaves or extraction of coca
             843      leaves, which extractions do not contain cocaine or ecgonine; and


             844          (E) Concentrate of poppy straw, which means the crude extract of poppy straw in either
             845      liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy.
             846          (ii) Unless specifically excepted or unless listed in another schedule, any of the
             847      following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
             848      ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific
             849      chemical designation, except dextrorphan and levopropoxyphene:
             850          (A) Alfentanil;
             851          (B) Alphaprodine;
             852          (C) Anileridine;
             853          (D) Bezitramide;
             854          (E) Bulk dextropropoxyphene (nondosage forms);
             855          (F) Carfentanil;
             856          (G) Dihydrocodeine;
             857          (H) Diphenoxylate;
             858          (I) Fentanyl;
             859          (J) Isomethadone;
             860          (K) Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol,
             861      levomethadyl acetate, or LAAM;
             862          (L) Levomethorphan;
             863          (M) Levorphanol;
             864          (N) Metazocine;
             865          (O) Methadone;
             866          (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
             867          (Q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic
             868      acid;
             869          (R) Pethidine (meperidine);
             870          (S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
             871          (T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;


             872          (U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
             873          (V) Phenazocine;
             874          (W) Piminodine;
             875          (X) Racemethorphan;
             876          (Y) Racemorphan;
             877          (Z) Remifentanil; and
             878          (AA) Sufentanil.
             879          (iii) Unless specifically excepted or unless listed in another schedule, any material,
             880      compound, mixture, or preparation which contains any quantity of the following substances
             881      having a stimulant effect on the central nervous system:
             882          (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
             883          (B) Methamphetamine, its salts, isomers, and salts of its isomers;
             884          (C) Phenmetrazine and its salts; and
             885          (D) Methylphenidate.
             886          (iv) Unless specifically excepted or unless listed in another schedule, any material,
             887      compound, mixture, or preparation which contains any quantity of the following substances
             888      having a depressant effect on the central nervous system, including its salts, isomers, and salts
             889      of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
             890      specific chemical designation:
             891          (A) Amobarbital;
             892          (B) Glutethimide;
             893          (C) Pentobarbital;
             894          (D) Phencyclidine;
             895          (E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and
             896      1-piperidinocyclohexanecarbonitrile (PCC); and
             897          (F) Secobarbital.
             898          (v) (A) Unless specifically excepted or unless listed in another schedule, any material,
             899      compound, mixture, or preparation which contains any quantity of Phenylacetone.


             900          (B) Some of these substances may be known by trade or other names:
             901      phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.
             902          (vi) Nabilone, another name for nabilone:
             903      (.)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,
             904      6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
             905          (c) Schedule III:
             906          (i) Unless specifically excepted or unless listed in another schedule, any material,
             907      compound, mixture, or preparation which contains any quantity of the following substances
             908      having a stimulant effect on the central nervous system, including its salts, isomers whether
             909      optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers,
             910      and salts of isomers is possible within the specific chemical designation:
             911          (A) Those compounds, mixtures, or preparations in dosage unit form containing any
             912      stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were
             913      listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the
             914      Code of Federal Regulations, and any other drug of the quantitive composition shown in that
             915      list for those drugs or which is the same except that it contains a lesser quantity of controlled
             916      substances;
             917          (B) Benzphetamine;
             918          (C) Chlorphentermine;
             919          (D) Clortermine; and
             920          (E) Phendimetrazine.
             921          (ii) Unless specifically excepted or unless listed in another schedule, any material,
             922      compound, mixture, or preparation which contains any quantity of the following substances
             923      having a depressant effect on the central nervous system:
             924          (A) Any compound, mixture, or preparation containing amobarbital, secobarbital,
             925      pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients
             926      which are not listed in any schedule;
             927          (B) Any suppository dosage form containing amobarbital, secobarbital, or


             928      pentobarbital, or any salt of any of these drugs which is approved by the Food and Drug
             929      Administration for marketing only as a suppository;
             930          (C) Any substance which contains any quantity of a derivative of barbituric acid or any
             931      salt of any of them;
             932          (D) Chlorhexadol;
             933          (E) Buprenorphine;
             934          (F) Any drug product containing gamma hydroxybutyric acid, including its salts,
             935      isomers, and salts of isomers, for which an application is approved under the federal Food,
             936      Drug, and Cosmetic Act, Section 505;
             937          (G) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine:
             938      . -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;
             939          (H) Lysergic acid;
             940          (I) Lysergic acid amide;
             941          (J) Methyprylon;
             942          (K) Sulfondiethylmethane;
             943          (L) Sulfonethylmethane;
             944          (M) Sulfonmethane; and
             945          (N) Tiletamine and zolazepam or any of their salts, some trade or other names for a
             946      tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine:
             947      2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam:
             948      4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one,
             949      flupyrazapon.
             950          (iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
             951      U.S. Food and Drug Administration approved drug product, some other names for dronabinol:
             952      (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or
             953      (-)-delta-9-(trans)-tetrahydrocannabinol.
             954          (iv) Nalorphine.
             955          (v) Unless specifically excepted or unless listed in another schedule, any material,


             956      compound, mixture, or preparation containing limited quantities of any of the following
             957      narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid:
             958          (A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
             959      milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of
             960      opium;
             961          (B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
             962      milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized
             963      therapeutic amounts;
             964          (C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more
             965      than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline
             966      alkaloid of opium;
             967          (D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more
             968      than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
             969      recognized therapeutic amounts;
             970          (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90
             971      milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized
             972      therapeutic amounts;
             973          (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more
             974      than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
             975      recognized therapeutic amounts;
             976          (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not
             977      more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
             978      recognized therapeutic amounts; and
             979          (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with
             980      one or more active, non-narcotic ingredients in recognized therapeutic amounts.
             981          (vi) Unless specifically excepted or unless listed in another schedule, anabolic steroids
             982      including any of the following or any isomer, ester, salt, or derivative of the following that
             983      promotes muscle growth:


             984          (A) Boldenone;
             985          (B) Chlorotestosterone (4-chlortestosterone);
             986          (C) Clostebol;
             987          (D) Dehydrochlormethyltestosterone;
             988          (E) Dihydrotestosterone (4-dihydrotestosterone);
             989          (F) Drostanolone;
             990          (G) Ethylestrenol;
             991          (H) Fluoxymesterone;
             992          (I) Formebulone (formebolone);
             993          (J) Mesterolone;
             994          (K) Methandienone;
             995          (L) Methandranone;
             996          (M) Methandriol;
             997          (N) Methandrostenolone;
             998          (O) Methenolone;
             999          (P) Methyltestosterone;
             1000          (Q) Mibolerone;
             1001          (R) Nandrolone;
             1002          (S) Norethandrolone;
             1003          (T) Oxandrolone;
             1004          (U) Oxymesterone;
             1005          (V) Oxymetholone;
             1006          (W) Stanolone;
             1007          (X) Stanozolol;
             1008          (Y) Testolactone;
             1009          (Z) Testosterone; and
             1010          (AA) Trenbolone.
             1011          (vii) Anabolic steroids expressly intended for administration through implants to cattle


             1012      or other nonhuman species, and approved by the Secretary of Health and Human Services for
             1013      use, may not be classified as a controlled substance.
             1014          (d) Schedule IV:
             1015          (i) Unless specifically excepted or unless listed in another schedule, any material,
             1016      compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not
             1017      less than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them.
             1018          (ii) Unless specifically excepted or unless listed in another schedule, any material,
             1019      compound, mixture, or preparation which contains any quantity of the following substances,
             1020      including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and
             1021      salts of isomers is possible within the specific chemical designation:
             1022          (A) Alprazolam;
             1023          (B) Barbital;
             1024          (C) Bromazepam;
             1025          (D) Butorphanol;
             1026          (E) Camazepam;
             1027          (F) Carisoprodol;
             1028          (G) Chloral betaine;
             1029          (H) Chloral hydrate;
             1030          (I) Chlordiazepoxide;
             1031          (J) Clobazam;
             1032          (K) Clonazepam;
             1033          (L) Clorazepate;
             1034          (M) Clotiazepam;
             1035          (N) Cloxazolam;
             1036          (O) Delorazepam;
             1037          (P) Diazepam;
             1038          (Q) Dichloralphenazone;
             1039          (R) Estazolam;


             1040          (S) Ethchlorvynol;
             1041          (T) Ethinamate;
             1042          (U) Ethyl loflazepate;
             1043          (V) Fludiazepam;
             1044          (W) Flunitrazepam;
             1045          (X) Flurazepam;
             1046          (Y) Halazepam;
             1047          (Z) Haloxazolam;
             1048          (AA) Ketazolam;
             1049          (BB) Loprazolam;
             1050          (CC) Lorazepam;
             1051          (DD) Lormetazepam;
             1052          (EE) Mebutamate;
             1053          (FF) Medazepam;
             1054          (GG) Meprobamate;
             1055          (HH) Methohexital;
             1056          (II) Methylphenobarbital (mephobarbital);
             1057          (JJ) Midazolam;
             1058          (KK) Nimetazepam;
             1059          (LL) Nitrazepam;
             1060          (MM) Nordiazepam;
             1061          (NN) Oxazepam;
             1062          (OO) Oxazolam;
             1063          (PP) Paraldehyde;
             1064          (QQ) Pentazocine;
             1065          (RR) Petrichloral;
             1066          (SS) Phenobarbital;
             1067          (TT) Pinazepam;


             1068          (UU) Prazepam;
             1069          (VV) Quazepam;
             1070          (WW) Temazepam;
             1071          (XX) Tetrazepam;
             1072          (YY) Triazolam;
             1073          (ZZ) Zaleplon; and
             1074          (AAA) Zolpidem.
             1075          (iii) Any material, compound, mixture, or preparation of fenfluramine which contains
             1076      any quantity of the following substances, including its salts, isomers whether optical, position,
             1077      or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of
             1078      isomers is possible.
             1079          (iv) Unless specifically excepted or unless listed in another schedule, any material,
             1080      compound, mixture, or preparation which contains any quantity of the following substances
             1081      having a stimulant effect on the central nervous system, including its salts, isomers whether
             1082      optical, position, or geometric isomers, and salts of the isomers when the existence of the salts,
             1083      isomers, and salts of isomers is possible within the specific chemical designation:
             1084          (A) Cathine ((+)-norpseudoephedrine);
             1085          (B) Diethylpropion;
             1086          (C) Fencamfamine;
             1087          (D) Fenproprex;
             1088          (E) Mazindol;
             1089          (F) Mefenorex;
             1090          (G) Modafinil;
             1091          (H) Pemoline, including organometallic complexes and chelates thereof;
             1092          (I) Phentermine;
             1093          (J) Pipradrol;
             1094          (K) Sibutramine; and
             1095          (L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).


             1096          (v) Unless specifically excepted or unless listed in another schedule, any material,
             1097      compound, mixture, or preparation which contains any quantity of dextropropoxyphene
             1098      (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.
             1099          (e) Schedule V: Any compound, mixture, or preparation containing any of the
             1100      following limited quantities of narcotic drugs, or their salts calculated as the free anhydrous
             1101      base or alkaloid, which includes one or more non-narcotic active medicinal ingredients in
             1102      sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal
             1103      qualities other than those possessed by the narcotic drug alone:
             1104          (i) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
             1105          (ii) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100
             1106      grams;
             1107          (iii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100
             1108      grams;
             1109          (iv) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of
             1110      atropine sulfate per dosage unit;
             1111          (v) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
             1112          (vi) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of
             1113      atropine sulfate per dosage unit; and
             1114          (vii) unless specifically exempted or excluded or unless listed in another schedule, any
             1115      material, compound, mixture, or preparation which contains Pyrovalerone having a stimulant
             1116      effect on the central nervous system, including its salts, isomers, and salts of isomers.
             1117          Section 6. Section 58-37-4.2 is enacted to read:
             1118          58-37-4.2. Listed controlled substances.
             1119          The following substances, their analogs, homologs, and synthetic equivalents are listed
             1120      controlled substances:
             1121          (1) AM-694;1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone;
             1122          (2) CP 47,497 and its C6, C8, and C9 homologs; 2-[(1R,3S)-3-hydroxycyclohexyl]
             1123      -5-(2-methyloctan-2-yl)phenol;


             1124          (3) HU-210; (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
             1125      -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
             1126          (4) HU-211; Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
             1127      methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
             1128          (5) JWH-015; (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone;
             1129          (6) JWH-018; Naphthalen-1-yl-(pentylindol-3-yl)methanone {also known as
             1130      1-Pentyl-3-(1-naphthoyl)indole};
             1131          (7) JWH-019; 1-hexyl-3-(1-naphthoyl)indole;              1132          (8) JWH-073; Naphthalen-1-yl(1-butylindol-3-yl)methanone {also known as
             1133      1-Butyl-3-(1-naphthoyl)indole};
             1134          (9) JWH-081; 4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone;
             1135          (10) JWH-122; CAS#619294-47-2; (1-Pentyl-3-(4-methyl-1-naphthoyl)indole);
             1136          (11) JWH-200; 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
             1137          (12) JWH-250; 1-pentyl-3-(2-methoxyphenylacetyl)indole;
             1138          (13) JWH-251; 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone;
             1139          (14) JWH-398; 1-pentyl-3-(4-chloro-1-naphthoyl)indole;
             1140          (15) RCS-8; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole {also known as
             1141      BTW-8 and SR-18};
             1142          (16) 4-methylmethcathinone {also known as mephedrone};
             1143          (17) 3,4-methylenedioxypyrovalerone {also known as MDPV};
             1144          (18) 3,4-Methylenedioxymethcathinone {also known as methylone};
             1145          (19) 4-methoxymethcathinone;
             1146          (20) 4-Fluoromethcathinone; and
             1147          (21) 3-Fluoromethcathinone.
             1148          Section 7. Section 58-37-6 is amended to read:
             1149           58-37-6. License to manufacture, produce, distribute, dispense, administer, or
             1150      conduct research -- Issuance by division -- Denial, suspension, or revocation -- Records
             1151      required -- Prescriptions.


             1152          (1) (a) The division may adopt rules relating to the licensing and control of the
             1153      manufacture, distribution, production, prescription, administration, dispensing, conducting of
             1154      research with, and performing of laboratory analysis upon controlled substances within this
             1155      state.
             1156          (b) The division may assess reasonable fees to defray the cost of issuing original and
             1157      renewal licenses under this chapter pursuant to Section 63J-1-504 .
             1158          (2) (a) (i) Every person who manufactures, produces, distributes, prescribes, dispenses,
             1159      administers, conducts research with, or performs laboratory analysis upon any controlled
             1160      substance in Schedules II through V within this state, or who proposes to engage in
             1161      manufacturing, producing, distributing, prescribing, dispensing, administering, conducting
             1162      research with, or performing laboratory analysis upon controlled substances included in
             1163      Schedules II through V within this state shall obtain a license issued by the division.
             1164          (ii) The division shall issue each license under this chapter in accordance with a
             1165      two-year renewal cycle established by rule. The division may by rule extend or shorten a
             1166      renewal period by as much as one year to stagger the renewal cycles it administers.
             1167          (b) Persons licensed to manufacture, produce, distribute, prescribe, dispense,
             1168      administer, conduct research with, or perform laboratory analysis upon controlled substances in
             1169      Schedules II through V within this state may possess, manufacture, produce, distribute,
             1170      prescribe, dispense, administer, conduct research with, or perform laboratory analysis upon
             1171      those substances to the extent authorized by their license and in conformity with this chapter.
             1172          (c) The following persons are not required to obtain a license and may lawfully possess
             1173      controlled substances under this section:
             1174          (i) an agent or employee, except a sales representative, of any registered manufacturer,
             1175      distributor, or dispenser of any controlled substance, if the agent or employee is acting in the
             1176      usual course of the person's business or employment; however, nothing in this subsection shall
             1177      be interpreted to permit an agent, employee, sales representative, or detail man to maintain an
             1178      inventory of controlled substances separate from the location of the person's employer's
             1179      registered and licensed place of business;


             1180          (ii) a motor carrier or warehouseman, or an employee of a motor carrier or
             1181      warehouseman, who possesses any controlled substance in the usual course of the person's
             1182      business or employment; and
             1183          (iii) an ultimate user, or any person who possesses any controlled substance pursuant to
             1184      a lawful order of a practitioner.
             1185          (d) The division may enact rules waiving the license requirement for certain
             1186      manufacturers, producers, distributors, prescribers, dispensers, administrators, research
             1187      practitioners, or laboratories performing analysis if consistent with the public health and safety.
             1188          (e) A separate license is required at each principal place of business or professional
             1189      practice where the applicant manufactures, produces, distributes, dispenses, conducts research
             1190      with, or performs laboratory analysis upon controlled substances.
             1191          (f) The division may enact rules providing for the inspection of a licensee or applicant's
             1192      establishment, and may inspect the establishment according to those rules.
             1193          (3) (a) Upon proper application, the division shall license a qualified applicant to
             1194      manufacture, produce, distribute, conduct research with, or perform laboratory analysis upon
             1195      controlled substances included in Schedules I through V, unless it determines that issuance of a
             1196      license is inconsistent with the public interest. The division shall not issue a license to any
             1197      person to prescribe, dispense, or administer a Schedule I controlled substance. In determining
             1198      public interest, the division shall consider whether or not the applicant has:
             1199          (i) maintained effective controls against diversion of controlled substances and any
             1200      Schedule I or II substance compounded from any controlled substance into other than
             1201      legitimate medical, scientific, or industrial channels;
             1202          (ii) complied with applicable state and local law;
             1203          (iii) been convicted under federal or state laws relating to the manufacture, distribution,
             1204      or dispensing of substances;
             1205          (iv) past experience in the manufacture of controlled dangerous substances;
             1206          (v) established effective controls against diversion; and
             1207          (vi) complied with any other factors that the division establishes that promote the


             1208      public health and safety.
             1209          (b) Licenses granted under Subsection (3)(a) do not entitle a licensee to manufacture,
             1210      produce, distribute, conduct research with, or perform laboratory analysis upon controlled
             1211      substances in Schedule I other than those specified in the license.
             1212          (c) (i) Practitioners shall be licensed to administer, dispense, or conduct research with
             1213      substances in Schedules II through V if they are authorized to administer, dispense, or conduct
             1214      research under the laws of this state.
             1215          (ii) The division need not require a separate license for practitioners engaging in
             1216      research with nonnarcotic controlled substances in Schedules II through V where the licensee is
             1217      already licensed under this chapter in another capacity.
             1218          (iii) With respect to research involving narcotic substances in Schedules II through V,
             1219      or where the division by rule requires a separate license for research of nonnarcotic substances
             1220      in Schedules II through V, a practitioner shall apply to the division prior to conducting
             1221      research.
             1222          (iv) Licensing for purposes of bona fide research with controlled substances by a
             1223      practitioner considered qualified may be denied only on a ground specified in Subsection (4),
             1224      or upon evidence that the applicant will abuse or unlawfully transfer or fail to safeguard
             1225      adequately the practitioner's supply of substances against diversion from medical or scientific
             1226      use.
             1227          (v) Practitioners registered under federal law to conduct research in Schedule I
             1228      substances may conduct research in Schedule I substances within this state upon furnishing the
             1229      division evidence of federal registration.
             1230          (d) Compliance by manufacturers, producers, and distributors with the provisions of
             1231      federal law respecting registration, excluding fees, entitles them to be licensed under this
             1232      chapter.
             1233          (e) The division shall initially license those persons who own or operate an
             1234      establishment engaged in the manufacture, production, distribution, dispensation, or
             1235      administration of controlled substances prior to April 3, 1980, and who are licensed by the


             1236      state.
             1237          (4) (a) Any license pursuant to Subsection (2) or (3) may be denied, suspended, placed
             1238      on probation, or revoked by the division upon finding that the applicant or licensee has:
             1239          (i) materially falsified any application filed or required pursuant to this chapter;
             1240          (ii) been convicted of an offense under this chapter or any law of the United States, or
             1241      any state, relating to any substance defined as a controlled substance;
             1242          (iii) been convicted of a felony under any other law of the United States or any state
             1243      within five years of the date of the issuance of the license;
             1244          (iv) had a federal license denied, suspended, or revoked by competent federal authority
             1245      and is no longer authorized to engage in the manufacturing, distribution, or dispensing of
             1246      controlled substances;
             1247          (v) had the licensee's license suspended or revoked by competent authority of another
             1248      state for violation of laws or regulations comparable to those of this state relating to the
             1249      manufacture, distribution, or dispensing of controlled substances;
             1250          (vi) violated any division rule that reflects adversely on the licensee's reliability and
             1251      integrity with respect to controlled substances;
             1252          (vii) refused inspection of records required to be maintained under this chapter by a
             1253      person authorized to inspect them; or
             1254          (viii) prescribed, dispensed, administered, or injected an anabolic steroid for the
             1255      purpose of manipulating human hormonal structure so as to:
             1256          (A) increase muscle mass, strength, or weight without medical necessity and without a
             1257      written prescription by any practitioner in the course of the practitioner's professional practice;
             1258      or
             1259          (B) improve performance in any form of human exercise, sport, or game.
             1260          (b) The division may limit revocation or suspension of a license to a particular
             1261      controlled substance with respect to which grounds for revocation or suspension exist.
             1262          (c) (i) Proceedings to deny, revoke, or suspend a license shall be conducted pursuant to
             1263      this section and in accordance with the procedures set forth in Title 58, Chapter 1, Division of


             1264      Occupational and Professional Licensing Act, and conducted in conjunction with the
             1265      appropriate representative committee designated by the director of the department.
             1266          (ii) Nothing in this Subsection (4)(c) gives the Division of Occupational and
             1267      Professional Licensing exclusive authority in proceedings to deny, revoke, or suspend licenses,
             1268      except where the division is designated by law to perform those functions, or, when not
             1269      designated by law, is designated by the executive director of the Department of Commerce to
             1270      conduct the proceedings.
             1271          (d) (i) The division may suspend any license simultaneously with the institution of
             1272      proceedings under this section if it finds there is an imminent danger to the public health or
             1273      safety.
             1274          (ii) Suspension shall continue in effect until the conclusion of proceedings, including
             1275      judicial review, unless withdrawn by the division or dissolved by a court of competent
             1276      jurisdiction.
             1277          (e) (i) If a license is suspended or revoked under this Subsection (4), all controlled
             1278      substances owned or possessed by the licensee may be placed under seal in the discretion of the
             1279      division.
             1280          (ii) Disposition may not be made of substances under seal until the time for taking an
             1281      appeal has lapsed, or until all appeals have been concluded, unless a court, upon application,
             1282      orders the sale of perishable substances and the proceeds deposited with the court.
             1283          (iii) If a revocation order becomes final, all controlled substances shall be forfeited.
             1284          (f) The division shall notify promptly the Drug Enforcement Administration of all
             1285      orders suspending or revoking a license and all forfeitures of controlled substances.
             1286          (5) (a) Persons licensed under Subsection (2) or (3) shall maintain records and
             1287      inventories in conformance with the record keeping and inventory requirements of federal and
             1288      state law and any additional rules issued by the division.
             1289          (b) (i) Every physician, dentist, naturopathic physician, veterinarian, practitioner, or
             1290      other person who is authorized to administer or professionally use a controlled substance shall
             1291      keep a record of the drugs received by him and a record of all drugs administered, dispensed, or


             1292      professionally used by him otherwise than by a prescription.
             1293          (ii) A person using small quantities or solutions or other preparations of those drugs for
             1294      local application has complied with this Subsection (5)(b) if the person keeps a record of the
             1295      quantity, character, and potency of those solutions or preparations purchased or prepared by
             1296      him, and of the dates when purchased or prepared.
             1297          (6) Controlled substances in Schedules I through V may be distributed only by a
             1298      licensee and pursuant to an order form prepared in compliance with division rules or a lawful
             1299      order under the rules and regulations of the United States.
             1300          (7) (a) A person may not write or authorize a prescription for a controlled substance
             1301      unless the person is:
             1302          (i) a practitioner authorized to prescribe drugs and medicine under the laws of this state
             1303      or under the laws of another state having similar standards; and
             1304          (ii) licensed under this chapter or under the laws of another state having similar
             1305      standards.
             1306          (b) A person other than a pharmacist licensed under the laws of this state, or the
             1307      pharmacist's licensed intern, as required by Sections 58-17b-303 and 58-17b-304 , may not
             1308      dispense a controlled substance.
             1309          (c) (i) A controlled substance may not be dispensed without the written prescription of
             1310      a practitioner, if the written prescription is required by the federal Controlled Substances Act.
             1311          (ii) That written prescription shall be made in accordance with Subsection (7)(a) and in
             1312      conformity with Subsection (7)(d).
             1313          (iii) In emergency situations, as defined by division rule, controlled substances may be
             1314      dispensed upon oral prescription of a practitioner, if reduced promptly to writing on forms
             1315      designated by the division and filed by the pharmacy.
             1316          (iv) Prescriptions reduced to writing by a pharmacist shall be in conformity with
             1317      Subsection (7)(d).
             1318          (d) Except for emergency situations designated by the division, a person may not issue,
             1319      fill, compound, or dispense a prescription for a controlled substance unless the prescription is


             1320      signed by the prescriber in ink or indelible pencil or is signed with an electronic signature of
             1321      the prescriber as authorized by division rule, and contains the following information:
             1322          (i) the name, address, and registry number of the prescriber;
             1323          (ii) the name, address, and age of the person to whom or for whom the prescription is
             1324      issued;
             1325          (iii) the date of issuance of the prescription; and
             1326          (iv) the name, quantity, and specific directions for use by the ultimate user of the
             1327      controlled substance.
             1328          (e) A prescription may not be written, issued, filled, or dispensed for a Schedule I
             1329      controlled substance.
             1330          (f) Except when administered directly to an ultimate user by a licensed practitioner,
             1331      controlled substances are subject to the following restrictions:
             1332          (i) (A) A prescription for a Schedule II substance may not be refilled.
             1333          (B) A Schedule II controlled substance may not be filled in a quantity to exceed a
             1334      one-month's supply, as directed on the daily dosage rate of the prescriptions.
             1335          (ii) A Schedule III or IV controlled substance may be filled only within six months of
             1336      issuance, and may not be refilled more than six months after the date of its original issuance or
             1337      be refilled more than five times after the date of the prescription unless renewed by the
             1338      practitioner.
             1339          (iii) All other controlled substances in Schedule V may be refilled as the prescriber's
             1340      prescription directs, but they may not be refilled one year after the date the prescription was
             1341      issued unless renewed by the practitioner.
             1342          (iv) Any prescription for a Schedule II substance may not be dispensed if it is not
             1343      presented to a pharmacist for dispensing by a pharmacist or a pharmacy intern within 30 days
             1344      after the date the prescription was issued, or 30 days after the dispensing date, if that date is
             1345      specified separately from the date of issue.
             1346          (v) A practitioner may issue more than one prescription at the same time for the same
             1347      Schedule II controlled substance, but only under the following conditions:


             1348          (A) no more than three prescriptions for the same Schedule II controlled substance may
             1349      be issued at the same time;
             1350          (B) no one prescription may exceed a 30-day supply;
             1351          (C) a second or third prescription shall include the date of issuance and the date for
             1352      dispensing; and
             1353          (D) unless the practitioner determines there is a valid medical reason to the contrary,
             1354      the date for dispensing a second or third prescription may not be fewer than 30 days from the
             1355      dispensing date of the previous prescription.
             1356          (vi) Each prescription for a controlled substance may contain only one controlled
             1357      substance per prescription form and may not contain any other legend drug or prescription
             1358      item.
             1359          (g) An order for a controlled substance in Schedules II through V for use by an
             1360      inpatient or an outpatient of a licensed hospital is exempt from all requirements of this
             1361      Subsection (7) if the order is:
             1362          (i) issued or made by a prescribing practitioner who holds an unrestricted registration
             1363      with the federal Drug Enforcement Administration, and an active Utah controlled substance
             1364      license in good standing issued by the division under this section, or a medical resident who is
             1365      exempted from licensure under Subsection 58-1-307 (1)(c);
             1366          (ii) authorized by the prescribing practitioner treating the patient and the prescribing
             1367      practitioner designates the quantity ordered;
             1368          (iii) entered upon the record of the patient, the record is signed by the prescriber
             1369      affirming the prescriber's authorization of the order within 48 hours after filling or
             1370      administering the order, and the patient's record reflects the quantity actually administered; and
             1371          (iv) filled and dispensed by a pharmacist practicing the pharmacist's profession within
             1372      the physical structure of the hospital, or the order is taken from a supply lawfully maintained by
             1373      the hospital and the amount taken from the supply is administered directly to the patient
             1374      authorized to receive it.
             1375          (h) A practitioner licensed under this chapter may not prescribe, administer, or


             1376      dispense a controlled substance to a child, without first obtaining the consent required in
             1377      Section 78B-3-406 of a parent, guardian, or person standing in loco parentis of the child except
             1378      in cases of an emergency. For purposes of this Subsection (7)(h), "child" has the same
             1379      meaning as defined in Section 78A-6-105 , and "emergency" means any physical condition
             1380      requiring the administration of a controlled substance for immediate relief of pain or suffering.
             1381          (i) A practitioner licensed under this chapter may not prescribe or administer dosages
             1382      of a controlled substance in excess of medically recognized quantities necessary to treat the
             1383      ailment, malady, or condition of the ultimate user.
             1384          (j) A practitioner licensed under this chapter may not prescribe, administer, or dispense
             1385      any controlled substance to another person knowing that the other person is using a false name,
             1386      address, or other personal information for the purpose of securing the controlled substance.
             1387          (k) A person who is licensed under this chapter to manufacture, distribute, or dispense
             1388      a controlled substance may not manufacture, distribute, or dispense a controlled substance to
             1389      another licensee or any other authorized person not authorized by this license.
             1390          (l) A person licensed under this chapter may not omit, remove, alter, or obliterate a
             1391      symbol required by this chapter or by a rule issued under this chapter.
             1392          (m) A person licensed under this chapter may not refuse or fail to make, keep, or
             1393      furnish any record notification, order form, statement, invoice, or information required under
             1394      this chapter.
             1395          (n) A person licensed under this chapter may not refuse entry into any premises for
             1396      inspection as authorized by this chapter.
             1397          (o) A person licensed under this chapter may not furnish false or fraudulent material
             1398      information in any application, report, or other document required to be kept by this chapter or
             1399      willfully make any false statement in any prescription, order, report, or record required by this
             1400      chapter.
             1401          (8) (a) (i) Any person licensed under this chapter who is found by the division to have
             1402      violated any of the provisions of Subsections (7)(k) through (7)(o) or Subsection (10) is subject
             1403      to a penalty not to exceed $5,000. The division shall determine the procedure for adjudication


             1404      of any violations in accordance with Sections 58-1-106 and 58-1-108 .
             1405          (ii) The division shall deposit all penalties collected under Subsection (8)(a)(i) in the
             1406      General Fund as a dedicated credit to be used by the division under Subsection 58-37f-502 (1).
             1407          (b) Any person who knowingly and intentionally violates Subsections (7)(h) through
             1408      (7)(j) or Subsection (10) is:
             1409          (i) upon first conviction, guilty of a class B misdemeanor;
             1410          (ii) upon second conviction, guilty of a class A misdemeanor; and
             1411          (iii) on third or subsequent conviction, guilty of a third degree felony.
             1412          (c) Any person who knowingly and intentionally violates Subsections (7)(k) through
             1413      (7)(o) shall upon conviction be guilty of a third degree felony.
             1414          (9) Any information communicated to any licensed practitioner in an attempt to
             1415      unlawfully procure, or to procure the administration of, a controlled substance is not considered
             1416      to be a privileged communication.
             1417          (10) A person holding a valid license under this chapter who is engaged in medical
             1418      research may produce, possess, or administer, but may not prescribe or dispense, a controlled
             1419      substance listed in Section 58-37-4.2 .
             1420          Section 8. Section 58-37-8 is amended to read:
             1421           58-37-8. Prohibited acts -- Penalties.
             1422          (1) Prohibited acts A -- Penalties:
             1423          (a) Except as authorized by this chapter, it is unlawful for any person to knowingly and
             1424      intentionally:
             1425          (i) produce, manufacture, or dispense, or to possess with intent to produce,
             1426      manufacture, or dispense, a controlled or counterfeit substance;
             1427          (ii) distribute a controlled or counterfeit substance, or to agree, consent, offer, or
             1428      arrange to distribute a controlled or counterfeit substance;
             1429          (iii) possess a controlled or counterfeit substance with intent to distribute; or
             1430          (iv) engage in a continuing criminal enterprise where:
             1431          (A) the person participates, directs, or engages in conduct which results in any


             1432      violation of any provision of Title 58, Chapters 37, 37a, 37b, 37c, or 37d that is a felony; and
             1433          (B) the violation is a part of a continuing series of two or more violations of Title 58,
             1434      Chapters 37, 37a, 37b, 37c, or 37d on separate occasions that are undertaken in concert with
             1435      five or more persons with respect to whom the person occupies a position of organizer,
             1436      supervisor, or any other position of management.
             1437          (b) Any person convicted of violating Subsection (1)(a) with respect to:
             1438          (i) a substance or a counterfeit of a substance classified in Schedule I or II, a controlled
             1439      substance analog, or gammahydroxybutyric acid as listed in Schedule III is guilty of a second
             1440      degree felony and upon a second or subsequent conviction is guilty of a first degree felony;
             1441          (ii) a substance or a counterfeit of a substance classified in Schedule III or IV, or
             1442      marijuana, or a substance listed in Section 58-37-4.2 is guilty of a third degree felony, and
             1443      upon a second or subsequent conviction is guilty of a second degree felony; or
             1444          (iii) a substance or a counterfeit of a substance classified in Schedule V is guilty of a
             1445      class A misdemeanor and upon a second or subsequent conviction is guilty of a third degree
             1446      felony.
             1447          (c) Any person who has been convicted of a violation of Subsection (1)(a)(ii) or (iii)
             1448      may be sentenced to imprisonment for an indeterminate term as provided by law, but if the trier
             1449      of fact finds a firearm as defined in Section 76-10-501 was used, carried, or possessed on his
             1450      person or in his immediate possession during the commission or in furtherance of the offense,
             1451      the court shall additionally sentence the person convicted for a term of one year to run
             1452      consecutively and not concurrently; and the court may additionally sentence the person
             1453      convicted for an indeterminate term not to exceed five years to run consecutively and not
             1454      concurrently.
             1455          (d) Any person convicted of violating Subsection (1)(a)(iv) is guilty of a first degree
             1456      felony punishable by imprisonment for an indeterminate term of not less than seven years and
             1457      which may be for life. Imposition or execution of the sentence may not be suspended, and the
             1458      person is not eligible for probation.
             1459          (2) Prohibited acts B -- Penalties:


             1460          (a) It is unlawful:
             1461          (i) for any person knowingly and intentionally to possess or use a controlled substance
             1462      analog or a controlled substance, unless it was obtained under a valid prescription or order,
             1463      directly from a practitioner while acting in the course of the person's professional practice, or as
             1464      otherwise authorized by this chapter;
             1465          (ii) for any owner, tenant, licensee, or person in control of any building, room,
             1466      tenement, vehicle, boat, aircraft, or other place knowingly and intentionally to permit them to
             1467      be occupied by persons unlawfully possessing, using, or distributing controlled substances in
             1468      any of those locations; or
             1469          (iii) for any person knowingly and intentionally to possess an altered or forged
             1470      prescription or written order for a controlled substance.
             1471          (b) Any person convicted of violating Subsection (2)(a)(i) with respect to:
             1472          (i) marijuana, if the amount is 100 pounds or more, is guilty of a second degree felony;
             1473          (ii) a substance classified in Schedule I or II, marijuana, if the amount is more than 16
             1474      ounces, but less than 100 pounds, or a controlled substance analog, is guilty of a third degree
             1475      felony; or
             1476          (iii) marijuana, if the marijuana is not in the form of an extracted resin from any part of
             1477      the plant, and the amount is more than one ounce but less than 16 ounces, is guilty of a class A
             1478      misdemeanor.
             1479          (c) Upon a person's conviction of a violation of this Subsection (2) subsequent to a
             1480      conviction under Subsection (1)(a), that person shall be sentenced to a one degree greater
             1481      penalty than provided in this Subsection (2).
             1482          (d) Any person who violates Subsection (2)(a)(i) with respect to all other controlled
             1483      substances not included in Subsection (2)(b)(i), (ii), or (iii), including a substance listed in
             1484      Section 58-37-4.2 , or less than one ounce of marijuana, is guilty of a class B misdemeanor.
             1485      Upon a second conviction the person is guilty of a class A misdemeanor, and upon a third or
             1486      subsequent conviction the person is guilty of a third degree felony.
             1487          (e) Any person convicted of violating Subsection (2)(a)(i) while inside the exterior


             1488      boundaries of property occupied by any correctional facility as defined in Section 64-13-1 or
             1489      any public jail or other place of confinement shall be sentenced to a penalty one degree greater
             1490      than provided in Subsection (2)(b), and if the conviction is with respect to controlled
             1491      substances as listed in:
             1492          (i) Subsection (2)(b), the person may be sentenced to imprisonment for an
             1493      indeterminate term as provided by law, and:
             1494          (A) the court shall additionally sentence the person convicted to a term of one year to
             1495      run consecutively and not concurrently; and
             1496          (B) the court may additionally sentence the person convicted for an indeterminate term
             1497      not to exceed five years to run consecutively and not concurrently; and
             1498          (ii) Subsection (2)(d), the person may be sentenced to imprisonment for an
             1499      indeterminate term as provided by law, and the court shall additionally sentence the person
             1500      convicted to a term of six months to run consecutively and not concurrently.
             1501          (f) Any person convicted of violating Subsection (2)(a)(ii) or [(2)(a)](iii) is:
             1502          (i) on a first conviction, guilty of a class B misdemeanor;
             1503          (ii) on a second conviction, guilty of a class A misdemeanor; and
             1504          (iii) on a third or subsequent conviction, guilty of a third degree felony.
             1505          (g) A person is subject to the penalties under Subsection (2)(h) who, in an offense not
             1506      amounting to a violation of Section 76-5-207 :
             1507          (i) violates Subsection (2)(a)(i) by knowingly and intentionally having in the person's
             1508      body any measurable amount of a controlled substance; and
             1509          (ii) operates a motor vehicle as defined in Section 76-5-207 in a negligent manner,
             1510      causing serious bodily injury as defined in Section 76-1-601 or the death of another.
             1511          (h) A person who violates Subsection (2)(g) by having in the person's body:
             1512          (i) a controlled substance classified under Schedule I, other than those described in
             1513      Subsection (2)(h)(ii), or a controlled substance classified under Schedule II is guilty of a second
             1514      degree felony;
             1515          (ii) marijuana, tetrahydrocannabinols, or equivalents described in Subsection


             1516      58-37-4 (2)(a)(iii)(S) or (AA), or a substance listed in Section 58-37-4.2 is guilty of a third
             1517      degree felony; or
             1518          (iii) any controlled substance classified under Schedules III, IV, or V is guilty of a class
             1519      A misdemeanor.
             1520          (i) A person is guilty of a separate offense for each victim suffering serious bodily
             1521      injury or death as a result of the person's negligent driving in violation of Subsection
             1522      58-37-8 (2)(g) whether or not the injuries arise from the same episode of driving.
             1523          (3) Prohibited acts C -- Penalties:
             1524          (a) It is unlawful for any person knowingly and intentionally:
             1525          (i) to use in the course of the manufacture or distribution of a controlled substance a
             1526      license number which is fictitious, revoked, suspended, or issued to another person or, for the
             1527      purpose of obtaining a controlled substance, to assume the title of, or represent oneself to be, a
             1528      manufacturer, wholesaler, apothecary, physician, dentist, veterinarian, or other authorized
             1529      person;
             1530          (ii) to acquire or obtain possession of, to procure or attempt to procure the
             1531      administration of, to obtain a prescription for, to prescribe or dispense to any person known to
             1532      be attempting to acquire or obtain possession of, or to procure the administration of any
             1533      controlled substance by misrepresentation or failure by the person to disclose receiving any
             1534      controlled substance from another source, fraud, forgery, deception, subterfuge, alteration of a
             1535      prescription or written order for a controlled substance, or the use of a false name or address;
             1536          (iii) to make any false or forged prescription or written order for a controlled substance,
             1537      or to utter the same, or to alter any prescription or written order issued or written under the
             1538      terms of this chapter; or
             1539          (iv) to make, distribute, or possess any punch, die, plate, stone, or other thing designed
             1540      to print, imprint, or reproduce the trademark, trade name, or other identifying mark, imprint, or
             1541      device of another or any likeness of any of the foregoing upon any drug or container or labeling
             1542      so as to render any drug a counterfeit controlled substance.
             1543          (b) Any person convicted of violating Subsection (3)(a) is guilty of a third degree


             1544      felony.
             1545          (4) Prohibited acts D -- Penalties:
             1546          (a) Notwithstanding other provisions of this section, a person not authorized under this
             1547      chapter who commits any act declared to be unlawful under this section, Title 58, Chapter 37a,
             1548      Utah Drug Paraphernalia Act, or under Title 58, Chapter 37b, Imitation Controlled Substances
             1549      Act, is upon conviction subject to the penalties and classifications under this Subsection (4) if
             1550      the trier of fact finds the act is committed:
             1551          (i) in a public or private elementary or secondary school or on the grounds of any of
             1552      those schools;
             1553          (ii) in a public or private vocational school or postsecondary institution or on the
             1554      grounds of any of those schools or institutions;
             1555          (iii) in those portions of any building, park, stadium, or other structure or grounds
             1556      which are, at the time of the act, being used for an activity sponsored by or through a school or
             1557      institution under Subsections (4)(a)(i) and (ii);
             1558          (iv) in or on the grounds of a preschool or child-care facility;
             1559          (v) in a public park, amusement park, arcade, or recreation center;
             1560          (vi) in or on the grounds of a house of worship as defined in Section 76-10-501 ;
             1561          (vii) in a shopping mall, sports facility, stadium, arena, theater, movie house,
             1562      playhouse, or parking lot or structure adjacent thereto;
             1563          (viii) in or on the grounds of a library;
             1564          (ix) within any area that is within 1,000 feet of any structure, facility, or grounds
             1565      included in Subsections (4)(a)(i), (ii), (iv), (vi), and (vii);
             1566          (x) in the presence of a person younger than 18 years of age, regardless of where the act
             1567      occurs; or
             1568          (xi) for the purpose of facilitating, arranging, or causing the transport, delivery, or
             1569      distribution of a substance in violation of this section to an inmate or on the grounds of any
             1570      correctional facility as defined in Section 76-8-311.3 .
             1571          (b) (i) A person convicted under this Subsection (4) is guilty of a first degree felony


             1572      and shall be imprisoned for a term of not less than five years if the penalty that would
             1573      otherwise have been established but for this Subsection (4) would have been a first degree
             1574      felony.
             1575          (ii) Imposition or execution of the sentence may not be suspended, and the person is
             1576      not eligible for probation.
             1577          (c) If the classification that would otherwise have been established would have been
             1578      less than a first degree felony but for this Subsection (4), a person convicted under this
             1579      Subsection (4) is guilty of one degree more than the maximum penalty prescribed for that
             1580      offense. This Subsection (4)(c) does not apply to a violation of Subsection (2)(g).
             1581          (d) (i) If the violation is of Subsection (4)(a)(xi):
             1582          (A) the person may be sentenced to imprisonment for an indeterminate term as
             1583      provided by law, and the court shall additionally sentence the person convicted for a term of
             1584      one year to run consecutively and not concurrently; and
             1585          (B) the court may additionally sentence the person convicted for an indeterminate term
             1586      not to exceed five years to run consecutively and not concurrently; and
             1587          (ii) the penalties under this Subsection (4)(d) apply also to any person who, acting with
             1588      the mental state required for the commission of an offense, directly or indirectly solicits,
             1589      requests, commands, coerces, encourages, or intentionally aids another person to commit a
             1590      violation of Subsection (4)(a)(xi).
             1591          (e) It is not a defense to a prosecution under this Subsection (4) that the actor
             1592      mistakenly believed the individual to be 18 years of age or older at the time of the offense or
             1593      was unaware of the individual's true age; nor that the actor mistakenly believed that the
             1594      location where the act occurred was not as described in Subsection (4)(a) or was unaware that
             1595      the location where the act occurred was as described in Subsection (4)(a).
             1596          (5) Any violation of this chapter for which no penalty is specified is a class B
             1597      misdemeanor.
             1598          (6) For purposes of penalty enhancement under Subsections (1)(b) and (2)(c), a plea of
             1599      guilty or no contest to a violation of this section which is held in abeyance under Title 77,


             1600      Chapter 2a, Pleas in Abeyance, is the equivalent of a conviction, even if the charge has been
             1601      subsequently reduced or dismissed in accordance with the plea in abeyance agreement.
             1602          (7) A person may be charged and sentenced for a violation of this section,
             1603      notwithstanding a charge and sentence for a violation of any other section of this chapter.
             1604          (8) (a) Any penalty imposed for violation of this section is in addition to, and not in
             1605      lieu of, any civil or administrative penalty or sanction authorized by law.
             1606          (b) Where violation of this chapter violates a federal law or the law of another state,
             1607      conviction or acquittal under federal law or the law of another state for the same act is a bar to
             1608      prosecution in this state.
             1609          (9) In any prosecution for a violation of this chapter, evidence or proof which shows a
             1610      person or persons produced, manufactured, possessed, distributed, or dispensed a controlled
             1611      substance or substances, is prima facie evidence that the person or persons did so with
             1612      knowledge of the character of the substance or substances.
             1613          (10) This section does not prohibit a veterinarian, in good faith and in the course of the
             1614      veterinarian's professional practice only and not for humans, from prescribing, dispensing, or
             1615      administering controlled substances or from causing the substances to be administered by an
             1616      assistant or orderly under the veterinarian's direction and supervision.
             1617          (11) Civil or criminal liability may not be imposed under this section on:
             1618          (a) any person registered under this chapter who manufactures, distributes, or possesses
             1619      an imitation controlled substance for use as a placebo or investigational new drug by a
             1620      registered practitioner in the ordinary course of professional practice or research; or
             1621          (b) any law enforcement officer acting in the course and legitimate scope of the
             1622      officer's employment.
             1623          (12) (a) Civil or criminal liability may not be imposed under this section on any Indian,
             1624      as defined in Subsection 58-37-2 (1)(v), who uses, possesses, or transports peyote for bona fide
             1625      traditional ceremonial purposes in connection with the practice of a traditional Indian religion
             1626      as defined in Subsection 58-37-2 (1)(w).
             1627          (b) In a prosecution alleging violation of this section regarding peyote as defined in


             1628      Subsection 58-37-4 (2)(a)(iii)(V), it is an affirmative defense that the peyote was used,
             1629      possessed, or transported by an Indian for bona fide traditional ceremonial purposes in
             1630      connection with the practice of a traditional Indian religion.
             1631          (c) (i) The defendant shall provide written notice of intent to claim an affirmative
             1632      defense under this Subsection (12) as soon as practicable, but not later than 10 days prior to
             1633      trial.
             1634          (ii) The notice shall include the specific claims of the affirmative defense.
             1635          (iii) The court may waive the notice requirement in the interest of justice for good
             1636      cause shown, if the prosecutor is not unfairly prejudiced by the lack of timely notice.
             1637          (d) The defendant shall establish the affirmative defense under this Subsection (12) by
             1638      a preponderance of the evidence. If the defense is established, it is a complete defense to the
             1639      charges.
             1640          (13) (a) It is an affirmative defense that the person produced, possessed, or
             1641      administered a controlled substance listed in Section 58-37-4.2 if the person:
             1642          (i) was engaged in medical research; and
             1643          (ii) was a holder of a valid license to possess controlled substances under Section
             1644      58-37-6 .
             1645          (b) It is not a defense under Subsection (13)(a) that the person prescribed or dispensed
             1646      a controlled substance listed in Section 58-37-4.2 .
             1647          (14) It is an affirmative defense that the person possessed, in the person's body, a
             1648      controlled substance listed in Section 58-37-4.2 if:
             1649          (a) the person was the subject of medical research conducted by a holder of a valid
             1650      license to possess controlled substances under Section 58-37-6 ; and
             1651          (b) the substance was administered to the person by the medical researcher.
             1652          [(13)] (15) If any provision of this chapter, or the application of any provision to any
             1653      person or circumstances, is held invalid, the remainder of this chapter shall be given effect
             1654      without the invalid provision or application.
             1655          (16) A legislative body of a political subdivision may not enact an ordinance that is


             1656      less restrictive than any provision of this chapter.
             1657          Section 9. Section 58-38a-203 is amended to read:
             1658           58-38a-203. Duties of the committee.
             1659          (1) The committee serves as a consultative and advisory body to the Legislature
             1660      regarding:
             1661          (a) the movement of a controlled substance from one schedule or list to another;
             1662          (b) the removal of a controlled substance from any schedule or list; and
             1663          (c) the designation of a substance as a controlled substance and the placement of the
             1664      substance in a designated schedule or list.
             1665          (2) On or before September 30 of each year, the committee shall submit to the Health
             1666      and Human Services Interim Committee a written report:
             1667          (a) [listing] describing any substances recommended by the committee for scheduling,
             1668      rescheduling, listing, or deletion from the schedules or list by the Legislature; and
             1669          (b) stating the reasons for the recommendation.
             1670          (3) In advising the Legislature regarding the need to add, delete, relist, or reschedule a
             1671      substance, the committee shall consider:
             1672          (a) the actual or probable abuse of the substance, including:
             1673          (i) the history and current pattern of abuse both in Utah and in other states;
             1674          (ii) the scope, duration, and significance of abuse;
             1675          (iii) the degree of actual or probable detriment to public health which may result from
             1676      abuse of the substance; and
             1677          (iv) the probable physical and social impact of widespread abuse of the substance;
             1678          (b) the biomedical hazard of the substance, including:
             1679          (i) its pharmacology, including the effects and modifiers of the effects of the substance;
             1680          (ii) its toxicology, acute and chronic toxicity, interaction with other substances,
             1681      whether controlled or not, and the degree to which it may cause psychological or physiological
             1682      dependence; and
             1683          (iii) the risk to public health and the particular susceptibility of segments of the


             1684      population;
             1685          (c) whether the substance is an immediate precursor, as defined in Section 58-37-2 , of
             1686      a substance that is currently a controlled substance;
             1687          (d) the current state of scientific knowledge regarding the substance, including whether
             1688      there is any acceptable means to safely use the substance under medical supervision;
             1689          (e) the relationship between the use of the substance and criminal activity, including
             1690      whether:
             1691          (i) persons engaged in illicit trafficking of the substance are also engaged in other
             1692      criminal activity;
             1693          (ii) the nature and relative profitability of manufacturing or delivering the substance
             1694      encourages illicit trafficking in the substance;
             1695          (iii) the commission of other crimes is one of the recognized effects of abuse of the
             1696      substance; and
             1697          (iv) addiction to the substance relates to the commission of crimes to facilitate the
             1698      continued use of the substance;
             1699          (f) whether the substance has been scheduled by other states; and
             1700          (g) whether the substance has any accepted medical use in treatment in the United
             1701      States.
             1702          (4) The committee's duties under this chapter do not include tobacco products as
             1703      defined in Section 59-14-102 or alcoholic beverages as defined in Section 32A-1-105 .
             1704          Section 10. Section 58-38a-204 is amended to read:
             1705           58-38a-204. Guidelines for scheduling or listing drugs.
             1706          (1) (a) The committee shall recommend placement of a substance in Schedule I if it
             1707      finds:
             1708          (i) that the substance has high potential for abuse; and
             1709          (ii) that an accepted standard has not been established for safe use in treatment for
             1710      medical purposes.
             1711          (b) The committee may recommend placement of a substance in Schedule I under


             1712      Section 58-37-4 if it finds that the substance is classified as a controlled substance in Schedule
             1713      I under federal law.
             1714          (2) (a) The committee shall recommend placement of a substance in Schedule II if it
             1715      finds that:
             1716          (i) the substance has high potential for abuse;
             1717          (ii) the substance has a currently accepted medical use in treatment in the United
             1718      States, or a currently accepted medical use subject to severe restrictions; and
             1719          (iii) the abuse of the substance may lead to severe psychological or physiological
             1720      dependence.
             1721          (b) The committee may recommend placement of a substance in Schedule II if it finds
             1722      that the substance is classified as a controlled substance in Schedule II under federal law.
             1723          (3) (a) The committee shall recommend placement of a substance in Schedule III if it
             1724      finds that:
             1725          (i) the substance has a potential for abuse that is less than the potential for substances
             1726      listed in Schedules I and II;
             1727          (ii) the substance has a currently accepted medical use in treatment in the United
             1728      States; and
             1729          (iii) abuse of the substance may lead to moderate or low physiological dependence or
             1730      high psychological dependence.
             1731          (b) The committee may recommend placement of a substance in Schedule III if it finds
             1732      that the substance is classified as a controlled substance in Schedule III under federal law.
             1733          (4) (a) The committee shall recommend placement of a substance in Schedule IV if it
             1734      finds that:
             1735          (i) the substance has a low potential for abuse relative to substances in Schedule III;
             1736          (ii) the substance has currently accepted medical use in treatment in the United States;
             1737      and
             1738          (iii) abuse of the substance may lead to limited physiological dependence or
             1739      psychological dependence relative to the substances in Schedule III.


             1740          (b) The committee may recommend placement of a substance in Schedule IV if it finds
             1741      that the substance is classified as a controlled substance in Schedule IV under federal law.
             1742          (5) (a) The committee shall recommend placement of a substance in Schedule V if it
             1743      finds that:
             1744          (i) the substance has low potential for abuse relative to the controlled substances listed
             1745      in Schedule IV;
             1746          (ii) the substance has currently accepted medical use in treatment in the United States;
             1747      and
             1748          (iii) the substance has limited physiological dependence or psychological dependence
             1749      liability relative to the controlled substances listed in Schedule IV.
             1750          (b) The committee may recommend placement of a substance in Schedule V under this
             1751      chapter if it finds that the substance is classified as a controlled substance in Schedule V under
             1752      federal law.
             1753          (6) The committee may recommend placement of a substance on a controlled substance
             1754      list if it finds that the substance has a potential for abuse and that an accepted standard has not
             1755      been established for safe use in treatment for medical purposes.
             1756          Section 11. Effective date.
             1757          If approved by two-thirds of all the members elected to each house, this bill takes effect
             1758      upon approval by the governor, or the day following the constitutional time limit of Utah
             1759      Constitution Article VII, Section 8, without the governor's signature, or in the case of a veto,
             1760      the date of veto override, except that the amendments to Section 58-37-2 (Effective 07/01/11)
             1761      take effect on July 1, 2011.


[Bill Documents][Bills Directory]